University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

2016

MECHANISMS AND CONSIQENCES OF LYSOSOMAL MEMBRANE
PERMEABILIZATION FOLLOWING EXPOSURE TO BIOACTIVE
PARTICLES
Forrest Connell Jessop

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Jessop, Forrest Connell, "MECHANISMS AND CONSIQENCES OF LYSOSOMAL MEMBRANE
PERMEABILIZATION FOLLOWING EXPOSURE TO BIOACTIVE PARTICLES" (2016). Graduate Student
Theses, Dissertations, & Professional Papers. 10893.
https://scholarworks.umt.edu/etd/10893

This Dissertation is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

MECHANISMS AND CONSIQENCES OF LYSOSOMAL MEMBRANE
PERMEABILIZATION FOLLOWING EXPOSURE TO BIOACTIVE PARTICLES
By
FORREST CONNELL JESSOP
B.S., UNIVERSITY OF UTAH, SALT LAKE CITY, UTAH, U.S.A . 2011

Dissertation
presented in partial fulfillment of the requirements
for the degree of

Doctor of Philosophy
in Toxicology

The University of Montana
Missoula, MT

Official Graduation Date (May 2016)

Approved by:

Scott Whittenburg, Dean of The Graduate School
Graduate School

Andrij Holian, Director
Center for Environmental Health Sciences

Elizabeth Putnam, Chair
Department of Biomedical and Pharmaceutical Sciences

Keven Roberts, Associate Professor
Center for Environmental Health Sciences

Christopher Migliaccio, Assistant Professor
Center for Environmental Health Science

John Hoidal, M.D. Chair
Department of Internal Medicine, University of Utah

ii

Jessop, Forrest, Ph.D., May 2016

Toxicology

MECHANISMS AND CONSEQUENCES OF LYSOSOMAL MEMBRANE
PERMEABILIZATION FOLLOWING EXPOSURE TO BIOACTIVE PARTICLES

Committee Chair: Andrij Holian

Abstract
Exposure to bioactive environmental particles and engineered nanoparticles are
a significant public health concern. Inhalation of bioactive particles can result in
chronic inflammation, which drives tissue remodeling and fibrosis. Furthermore,
chronic inflammation can increase individual susceptibility to other diseases
including cancer and autoimmune diseases. The macrophage is the critical cell in
particle clearance following exposure, and is central to the inflammatory
responses and tissue remodeling. Phagocytosed bioactive particles within
macrophages cause cytotoxicity and activation of the NLRP3 inflammasome,
outcomes that are both essential to inflammation and disease development.
However, mechanisms that regulate NLRP3 inflammasome activity and
cytotoxicity have not fully been elucidated. The objective of this body of work was
to further define common yet critical mechanisms that cause and/or mediate
NLRP3 inflammasome activity following exposure to bioactive particles. In these
studies we demonstrate that bioactive particles including silica and engineered
nanomaterials cause lysosome membrane permeabilization (LMP) and the
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release of lysosomal proteases, which precedes and facilitates NLRP3
inflammasome activation. Bioactive particles cause LMP through a mechanism
that requires phagolysosome acidification. LMP and the activation of the NLRP3
inflammasome are required for secretion of pro-inflammatory cytokines and the
alarmin High Mobility Group Box 1 (HMGB1). Once secreted, HMGB1 can further
drive NLRP3 inflammasome activity through sterile priming, similar to the nonsterile mechanism utilized by endotoxin. A second critical pathway for regulation
of the NLRP3 inflammasome was autophagy. Mice with macrophages deficient in
autophagy had greater inflammation and chronic disease following silica
exposure, supporting a protective anti-inflammatory role for autophagic activity.
Together, these data reveal novel critical mechanisms in the regulation of NLRP3
inflammasome activity following bioactive particle exposure, and provide multiple
potential therapeutic targets for the suppression of inflammation and disease.
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE

1.0. Inflammation and Chronic Disease
Interstitial lung disease (ILD) is a general term that encompasses 300+
disorders that affect the tissue surrounding the alveoli of the lung. Sarcoidosis,
idiopathic pulmonary fibrosis, extrinsic allergic alveolitis, drug-induced (such as
bleomycin) ILD, and pneumoconiosis are some of the most prevalent ILD [1]. Chronic
inflammation is a critical factor in the development of most ILD. Anti-inflammatory and
anti-fibrotic drugs are often used to slow disease progression, but unfortunately, there
are no cures for ILD once it has progressed to fibrosis. Poor understanding of the
mechanisms of chronic inflammation contributes to the inability to find a cure.
Pneumoconiosis and bleomycin-induced ILD involve chronic inflammation
resulting from particle-induced sterile injury. Crystalline silica is the primary exposure
in pneumoconiosis, while endogenous formed uric acid crystals causes sterile injury
and inflammation with bleomycin treatment [2, 3]. Similarly, exposure to bioactiveengineered nanomaterial (ENM) including Multi-walled Carbon Nanotubes (MWCNT)
and Titanium Nanobelts (TNB) results in significant sterile injury and ILD in vivo [4-7].
Since chronic inflammation is a primary driver of disease, we hypothesize that
particle exposure models may be used to identify mechanisms and therapeutic
targets common to multiple ILDs. An increasing number of reports demonstrate that
the active NLRP3 inflammasome, which is involved in sensing sterile injury, is a point
of convergence in chronic inflammatory signaling [8]. However, this knowledge has
not been translated into effective therapies. Although there is extensive information in
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vitro regarding how the NLRP3 inflammasome becomes activated, the more relevant
challenge arises in elucidating why the NLRP3 inflammasome remains active in vivo
in sterile chronic inflammatory diseases. This introduction reviews essential
information currently understood regarding the NRLP3 inflammasome, its activation
and regulation. Furthermore, it will outline important gaps of knowledge vital to the
aims of this research.

1.1. NLRP3 Inflammasome Sensing of Sterile Injury
NLRP3 (Nod-like Receptor containing a Pyrin domain 3) is one member of a larger
family of pattern recognition receptors (See Table 1). NLRP3 is considered the most
promiscuous receptor of the family, a property necessary for sensing a broad range
of exogenous and endogenous agonists following sterile injury. The receptor is
constitutively expressed in a non-oligomerized state in healthy cells, but oligomerizes
following sterile injury into the NLRP3 inflammasome complex [9]. The molecular
oligomerization event is reminiscent of the mechanisms resulting in the formation of
the apoptosome. Associated with the NLRP3 inflammasome complex is the adapter
protein ASC (Apoptosis-associated speck-like protein, also known as Caspaserecruitment domain or PYCARD), which facilitates the recruitment of pro-caspase-1.
Assembly of the NLRP3 inflammasome complex results in auto-proteolytic
processing of pro-caspase-1 to its active form. Active caspase-1 facilitates multiple
downstream events, including the processing of cytokines IL-1β and IL-18 to their
active forms. Once secreted, IL-1β has been reported to play a critical role in the
pyrogenic and neutrophilic response following sterile injury, and is important in the
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development of chronic disease [10]. The active NLRP3 inflammasome is also
involved in a caspase-1 mediated, pro-inflammatory cell death pathway termed
pyroptosis. Finally, through an undefined mechanism, the active NLRP3
inflammasome has been reported to regulate unconventional secretion of IL-1β [11].

Table 1: The Inflammasome and Mechanisms of Activation
Receptor
NLRP3

Activating Agents

Mechanisms for Activation

Pore-forming toxins

K+ efflux

UV radiation

Cytosolic lysosomal cathepsins

Endogenous Crystal Particles (Uric
Acid, Cholesterol, Amyloid Plaques)

Mitochondrial Re-localization
and ROS

Exogenous Crystals (Silica,
Asbestos, Engineered
Nanomaterials, Alum)

Cytosolic mtDNA
Mitochondrial cardiolipin
release

Extracellular ATP
NLRP1B

B. anthracis lethal toxin

NLRP1B cleavage

MDP
NLRC4

Gram-negative bacteria with type III
or IV secretion systems:

Bacterial Component + NLRC4
Phosphorylation

Cytosolic flagella
AIM2

dsDNA

dsDNA detection and binding

F. tularenis
L. monocytogenes

1.2. NLRP3 Inflammasome Activation in Macrophage
The pulmonary macrophage is a central cell in maintaining the immune balance and
sterility of the lung. Macrophage populations in the lungs are heterogeneous and
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present in multiple-compartments, including the alveolar and interstitial spaces. The
alveolar macrophage (AM) is a critical cell in phagocytosis and clearance of particles
following inhalation exposure. We have previously reported that innate immune
function, with a specific emphasis on macrophage activity, was sufficient to cause
inflammation and disease in a murine model of silicosis [12]. Others have reported
critical roles for the macrophage in other NLRP3 inflammasome mediated diseases
including atherosclerosis, which involves cholesterol crystal exposure [13]. Together,
these studies provide evidence that macrophages are the critical cell regulating the
inflammatory and fibrotic response following exposure to particles, whether
environmental or endogenously formed. Therefore, the studies in this dissertation are
primarily oriented around mechanisms of NLRP3 inflammasome persistence and
regulation in vivo.

1.3. Mechanisms of NLRP3 inflammasome activation
Activation of the NLRP3 inflammasome in macrophages requires two signals: 1) an
extracellular priming signal that activates NF-κB resulting in transcription/translation
of NLRP3 inflammasome components and cytokines, and 2) an agonist that interacts
with the NLR binding domain facilitating the oligomerization of the NLRP3
inflammasome. In macrophages exposed to particles in vitro, bacterial endotoxin
(LPS) is used as the priming agent. In sterile injury, priming is likely caused by other
host derived alarmins or Danger Associated Molecular Patterns (DAMPs). Under
basal conditions, NLRP3 and other inflammasome components are hyperubiquitinated to prevent activation and to provide targeting for degradation [14, 15].
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TLR signaling and activation of NF-κB has been reported to play an important role in
the de-ubiquitination of NLRP3 inflammasome components allowing for
oligomerization [14, 15].
Specific agonists that bind the NLRP3 receptor (Signal 2) facilitating
oligomerization have not been determined, though critical upstream events have
been identified. Phagocytosed silica and alum particles can cause lysosome
membrane permeabilization (LMP), resulting in leak of lysosomal contents into the
cytosol resulting in NLRP3 assembly and cytotoxicity [16]. Engineered nanomaterials
have also been reported to cause NLRP3 inflammasome activation via LMP [4, 5].
The lysosomal protease cathepsin B has specifically been implicated in activation of
the NLRP3 inflammasome [16], though the mechanism by which this occurs has not
been determined. Other, but perhaps less critical pathways of NLRP3 inflammasome
activation for bioactive particle exposures includes mitochondrial destabilization and
ROS, cytosolic mtDNA or Cardiolipin, and potassium efflux [9]. Mechanisms resulting
in NLRP3 inflammasome assembly are summarized in Table 1.

1.4. Signal 1: DAMPs and NLRP3 inflammasome priming
Danger Associated Molecular Patterns (DAMPs) are associated with cellular
injury and death, and include a broad class of endogenous proteins, lipids, particles,
and nucleic acids (See Table 2). DAMPs also include endogenously formed uric acid
and cholesterol crystals resulting from impaired metabolic processes, both of which
are capable of activating signal 2 (facilitating NLRP3 inflammasome assembly) [13,
2]. Most DAMPs do not act as signal 2, but are important in stimulating NF-κB activity
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(signal 1). DAMPs in this class are often termed alarmins, due to their inability to
directly cause cellular injury. DAMPs responsible for priming the NLRP3
inflammasome following bioactive particle exposure have not been fully elucidated in
vivo.
HMGB1 is a nuclear architectural protein that can be released from necrotic
cells, and actively secreted from macrophages via an unconventional secretion
pathway [17-20]. During stress, HMGB1 translocates from the nucleus into the
cytosol. Cytosolic HMGB1 has been reported to induce autophagy via binding to
Beclin-1 in fibroblasts [21]. Autophagy induction may act as a platform for packaging
of HMGB1 prior to unconventional secretion [11]. Macrophages have been shown to
actively secrete HMGB1 through an NLRP3 inflammasome and caspase-1-mediated
pathway following nigericin treatment and starvation, and with endotoxemia/infection
[11, 20]. Whether NLRP3 inflammasome activity is required for HMGB1 secretion in
particle-exposed macrophages has not been determined. Cellular necrosis,
apoptosis, and NLRP3 activation in macrophages are all observed with bioactive
particle exposure, which could potentially result in HMGB1 release. Secretion of
HMGB1 with particle exposure in vitro and vivo has not been assessed.
Once outside the cell, HMGB1 has been shown to bind TLRs (primarily TLR4,
but TLR2 and TLR9 when associated with other DAMPs, See Table 2) and the
Receptor for Advanced Glycation End Products (RAGE). Extracellular HMGB1 has
been reported to have either chemotactic or NF-κB-inducing activity depending upon
its redox state [22]. HMGB1 neutralization studies in a murine model of bleomycininduced lung injury demonstrated a critical role for HMGB1 in driving chronic disease
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[23]. Others have reported a role for HMGB1-nucleic acid complexes in inflammation
during autoimmune diseases, including Systemic Lupus Erythematous, which has
increased prevalence in individuals with pneumoconiosis [24, 10, 3, 25]. Together,
these reports support investigating HMGB1 and its role in particle-induced
inflammation and disease.

Table 2: DAMPs and Reported Activity in models of sterile injury
DAMP/Alarmin
HMGB1

Receptor

Ref

Associated Activity

TLR2*, TLR4, TLR9*,
RAGE, CD24

NF-kB (TLRs)

[26, 22, 27-30]

MAPK and NF-kB (RAGE)
Chemotaxis

Histones

TLR9

NF-κB

[31]

IL-1α

IL-1R

NF-κB

[32]

Cholesterol Crystals

NLRP3

Caspase-1

[13]

Uric Acid Crystals

NLRP3

Caspase-1

[2]

Hyaluronin

TLR2, TLR4

NF-κB

[33, 34]

ATP

NLRP3, P2X4

Caspase-1

[35, 36]

S100/Calgranulin

RAGE

NF-κB and generation of
ROS

[37, 38]

mtDNA

TLR9, TLR4

NF-κB

[39, 40]

B-amyloid

RAGE, NLRP3

Caspase-1

[41, 42]

NF-κB and ROS
Nucleic Acids
(RNA/DNA)

TLR9, TLR3

NF-κB

[43, 29, 44]

IL-33

IL-33R

TH2 signaling

[45]

Heparin sulfate

TLR4

NF-κB

[46]

Table 2: This is a non-comprehensive list of DAMPs that have been shown to be involved in sterile
injury. While not all DAMPs are involved in sterile injury following exposure to bioactive particles,
common pathways are activated, including priming of the NLRP3 inflammasome through NF-κB.
*HMGB1 specificity to these receptors has been shown when complexed to other DAMPs, including
nucleic acids or endosomes.
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1.5. Signal 2: NLRP3 Inflammasome activation following LMP
Phagocytosed particles can cause LMP (Signal 2), resulting in an intermediate
signal that facilitates the assembly of the NLRP3 inflammasome and the activation of
cell death pathways [47]. LMP is observed in vitro with particles known to cause
inflammation and disease in vivo, including silica, alum, and cholesterol crystals [13,
16]. This is also reported to be the case following exposure to various ENM as well
[4, 5]. Following particle phagocytosis, lysosomes fuse with the phagosome in order
to degrade the particle(s) and neutralize the threat, similar to mechanisms
responsible for elimination of pathogens. However, many particles are resistant to
lysosomal degradation, and consequently, the intracellular fate of particles within the
phagolysosome is not clear. While bioactive particles may cause LMP, mechanisms
responsible for permeabilization of the membrane have not been elucidated.
Downstream consequences of LMP include translocation of lysosomal hydrolases
and cathepsins into the cytosol, mitochondrial damage, and ROS. Cytosolic
cathepsin B has been reported to be critical for activation of NLRP3 inflammasome
[16], however other cathepsins could be involved in both NLRP3 inflammasome
activation and the cytotoxic response. Multiple mechanisms have been proposed for
how particles cause LMP. The most critical of these mechanisms are highlighted
below and illustrated in Figure 1:

1.5.1. Reactive Oxygen Species (ROS)- ROS damage to the inner and/or outer
leaflet of the phagolysosome could lead to lipid peroxidation. This has been proposed
as a mechanism of LMP for ischemia/reperfusion and radiation-induced injury [48,

18

49]. Within the lysosome, hydrogen peroxide produced from NADPH Oxidases could
potentially react with inter-lysosomal iron to generate ROS via Fenton reactions [50].
Utilization of iron chelators and antioxidants prevents LMP during oxidative stress
[48-50]. Direct injury to mitochondria (in the case of radiation) or mitochondrial injury
by cytosolic cathepsins following particle-induced LMP could potentially be a source
of ROS that enhance LMP. Direct evidence showing intra-lysosomal ROS-induced
LMP following particle exposure is non-existent, though the potential for this
mechanism remains plausible.

1.5.2. Direct particle-membrane interactions- A second potential mechanism of
particle-LMP is membrane perturbation via particle-membrane interactions. Directly
assessing particle-membrane interactions within macrophages has significant
technical challenges. Consequently, there is limited evidence of what changes take
place when particles directly interact with lysosomal membranes to cause LMP.
Silica nanoparticles have been reported to alter membrane fluidity and
integrity in situ [51]. Furthermore, silica particles have been reported to cause RBC
lysis [52], suggesting that particles can directly interact with membranes resulting in
permeabilization. Specific physiochemical characteristics of nanoparticles are
important in determining their pro-inflammatory potential [4-6, 53, 7], which would
support the notion that physiochemical characteristics of particles could also define
their LMP-inducing potential. We hypothesized that inhibiting lysosomal acidification,
which would also prevent degradation of the protein corona surrounding the
phagocytosed particle, would also prevent particle-induced LMP. These studies are
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included in Chapter 3 of this dissertation. While these studies do not directly address
mechanisms by which particles interact with the phagolysosome membranes and
cause LMP, they do provide supportive evidence for future studies on this subject.

1.5.3. Lysosomal proteases- There is a possibility that lysosomal proteases may
contribute to LMP by acting on specific proteins inside or on the outer membrane
leaflet. There are reports demonstrating a specific role for cathepsin B in facilitating
LMP following treatment with membrane detergents [54, 55]. The ability of cathepsins
to cause LMP may result from cleavage of lysosomal membrane proteins such as
LAMP1 or LAMP2 [56]. Others suggest that cathepsin B, once leaked, may further
enhance LMP by targeting lysosomal stabilizing proteins on the outer leaflet such as
Sphingosine Kinase 1 [54, 57]. Calpain, another lysosomal protease, has been
reported to play a role in LMP following ischemic and hypochlorous acid-induced
injury through targeting of the lysosomal stabilizing protein Hsp70 [58]. Nevertheless,
the contribution of lysosomal proteases to LMP following bioactive particle exposure
is not known. Generally, active cathepsin B is associated with most particle
exposures, however only certain particles cause LMP, supporting the notion that
cathepsin B would not be the defining factor in LMP. Consequently, we hypothesized
that cathepsin B would play a minimal role in particle-induce LMP. We assessed the
contribution of cathepsin B to LMP in Chapter 3 of this dissertation.
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Figure 1: Mechanisms of LMP. Most notable mechanisms proposed to induce LMP
following bioactive particle exposure. ROS has been proposed to cause LMP through
lipid peroxidation. Secondly, particles may directly interact with the membrane, and
the physiochemical characteristics of the particle would define its membraneinteracting potential. Finally, lysosomal proteases such as cathepsin B have been
implicated in LMP through targeting of lysosomal stabilizing proteins including
LAMP1/2.

1.6. Methods for detection of LMP
Detection of LMP following particle exposure has multiple technical
challenges. Often studies report LMP using lysomotropic dyes such as acridine
orange or LysoTracker™. These results can be difficult to interpret, since release of
lysomotropic dyes from lysosomal compartments into the cytosol or changes in
fluorescent profiles can be due to changes in ion pump activity or dye uptake, rather
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than perturbations in membrane integrity [59]. Therefore, these assays should not be
used as primary evidence of LMP and should be supported with other assays. Others
have successfully utilized fluorescent-labeled dextran of varied molecular weights to
assess LMP [16]. Effects of dextran on the particle or the lysosome need to be
accounted for in these studies. Furthermore, FITC undergoes quenching at low pH,
and therefore use of this fluorophore may complicate interpretation. An additional
important factor to consider is that the fluorescent-based assays discussed are
primarily qualitative or semi-quantitative. With the rapidly growing market of ENM,
more robust methods are needed to screen particles for their LMP-inducing potential
and downstream NLRP3 inflammasome activity. For these reasons, we adapted
methods recently developed by Aits et al [60], which utilize digitonin for selective
extraction of the cytosol following LMP. Cathepsin or other lysosomal enzyme activity
can then be quantified within the extracted cytosolic fraction.

1.7. Impaired lysosome integrity in persistent NLRP3 inflammasome activity
An increasing numbers of reports associate impaired lysosomal integrity with
chronic inflammatory disease [61, 62]. Consequently, the lysosome as a therapeutic
target is being explored for multiple disorders including liver fibrosis,
neurodegenerative diseases, cardiovascular disease, and lysosome storage
disorders. Extracellular lysosomal cysteine proteases have been implicated in
inflammation and tissue remodeling in lung disease [63]. Therefore, targeting
lysosomal stability or associated activity of lysosomal proteases may have broad
therapeutic merit. We hypothesize that LMP is a central mechanism driving persistent
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NLRP3 inflammasome activity in the lung in vivo. The contribution of LMP to
persistent NLRP3 inflammasome activity in vivo has not been shown with bioactive
particle exposure. These studies are included in Chapter 3.

1.8. Autophagy is a primary regulator of the activated NLRP3 inflammasome
Autophagic dysfunction is an emerging paradigm contributing to the toxicity of
ENM [62]. Dysfunction in autophagy is associated with multiple chronic inflammatory
diseases including Crohn’s Disease, Chronic Obstructive Pulmonary Disease and
Idiopathic Pulmonary Fibrosis [64]. Autophagy was initially identified within yeast cells
during starvation as a mechanism through which multi-protein structures are
sequestered, broken down into their basic amino acids, and recycled for cellular
survival. Autophagy is highly conserved across species in most cell types, and is
critical in other activities including capturing cytosolic pathogens, sequestering
damaged organelles, and unconventional secretion processes [65-67]. The
autophagic pathway has an almost limitless degradative capacity, and can break
down lipid droplets and nucleic acid complexes in addition to protein structures,
thereby providing the cell with new nutrient pools. Multiple cellular stress signals can
induce autophagy, the most notable being inhibition of mTORC1 and increases in
AMPK [67, 68]. Other autophagy activating signals include growth hormones,
hypoxia, and accumulation of misfolded proteins [67]. There are multiple forms of
autophagy, including macroautophagy, microautophagy, and chaperone-mediated
autophagy. While these other forms of autophagy may play a role in particle-induced
inflammation and disease, for the studies in this dissertation macroautophagy is the
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primary focus due to its ability to sequestering bulk or large structures resulting from
cellular damage. For convenience, macroautophagy will be termed autophagy
throughout the rest of the dissertation.
Activation of the autophagic pathway results in nucleation of Beclin-1 (Atg6),
Atg14L and PI3Kinase Class III, which generates phosphatidyl-inositol-3-phosphate
(PI3P). PI3P facilitates the recruitment of other Atg proteins. An Atg ubiquitination-like
conjugation system (that includes Atg12, Atg7, Atg5, and Atg16L1) catalyzes
phagophore elongation. During phagophore elongation, Microtubule-associated
protein 1A/1B-light chain 3 (LC3-I) is cleaved to LC3-II and incorporated into the
expanding membrane. LC3-II is a unique identifier of autophagic vesicles, and is
critical for targeting of cellular components to the autophagosome. Autophagy
specific chaperones, such as SQSTM1 (p62), bind ubiquitinated protein or organelle
surfaces, and with their cargo associate with LC3-II [69]. Once formed, the
autophagosome is a double membrane organelle, which makes it possible to
visualize using Transition Electron Microscopy [70]. Autophagic vesicles carrying their
cargo and chaperones eventually fuse with lysosomes, which are the primary
organelle for degradation and recycling. Consequently, impaired lysosome integrity
could also influence autophagy.
In addition to degrading damaged multi-protein complexes and organelles,
autophagy has been reported to play an important role in sequestration of NLRP3
and AIM inflammasomes, ASC, and pro-IL-1β [71, 72]. Therefore, autophagy could
be an important regulatory mechanism of chronic inflammation and cytotoxicity
following bioactive particle exposures. Lysosome impairment, and or direct
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impairment of the autophagic pathway, has been associated with increased
cytotoxicity [62]. Rare earth oxide nanoparticles have been reported to disrupt
autophagic flux through the lysosome, which contributes to NLRP3 inflammasome
persistence [73]. The impact of particle exposure on the autophagic pathway is not
clear, and the relative contribution of autophagy to inflammation and disease
following particle exposure has not been determined. Autophagy is a relatively new
topic in particle toxicology, and Chapter 4 presents studies focused on the
contribution of autophagy in macrophages to silica-induced cytotoxicity, inflammation
and disease.

1.9. Unifying Project Rationale
The overall objectives of these studies are to further our understanding of
mechanisms by which the NLRP3 inflammasome is activated and remains activated
contributing to the development of ILD. In this dissertation, we address multiple gaps
of knowledge associated with NLRP3 inflammasome activity including 1) defining the
endogenous sterile priming signal, 2) determine mechanisms required for particleinduced LMP and the contribution of LMP to NLRP3 inflammasome persistence and
HMGB1 release in vivo, and 3) determining the contribution of autophagy to particleinduced inflammation and disease. The central hypothesis is that persistent NLRP3
inflammasome activity is dependent upon lysosome membrane permeabilization and
sterile priming by the alarmin High Mobility Group Box 1 (HMGB1). Further, we
hypothesize that autophagy will be a critical regulatory mechanism for suppressing
particle-induced NLRP3 inflammasome activity. The overall rationale is that defining
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mechanisms regulating NLRP3 inflammasome activity will provide critical information
to reduce inflammation that drives chronic lung disease. The study rationale is
summarized in Figure 2.

Figure 2: Project Outline. Chapter 2 of this dissertation explores the hypothesis that
HMGB1 is the NLRP3 inflammasome-priming signal during particle-induced sterile
injury following MWCNT. Chapter 3 of this dissertation focuses on mechanisms by
which bioactive particles cause LMP, and contribution of LMP to persistent NLRP3
activity and HMGB1 release in vivo. Finally, Chapter 4 focuses on the contribution of
autophagy to regulating NLRP3 inflammasome activity, cytotoxicity, and chronic lung
disease following silica exposure.
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2.2. Abstract
Endotoxin is often used to activate NF-κB in vitro when assessing NLRP3
inflammasome activation by various exogenous particles including nanoparticles.
However, the endogenous source of this signal 1 is unknown. High Mobility Group
Box 1 (HMGB1) is known to play a critical role in acute lung injury, however the
potential contribution of the alarmin HMGB1 to NLRP3 Inflammasome activation has
not been determined in response to nanoparticles in vivo. In this study, the ability of
multi-walled carbon nanotubes (MWCNT) to cause release of HMGB1 in vitro and in
vivo, as well as the potential of HMGB1 to function as signal 1 in vitro and in vivo,
was determined. HMGB1 activity in vivo was assessed by administration of HMGB1
neutralization antibodies following MWCNT exposure. Caspase-1-/- mice were utilized
to elucidate the dependence of HMGB1 secretion on NLRP3 inflammasome activity.
MWCNT exposure increased extracellular HMGB1 levels in primary alveolar
macrophages from C57Bl/6 mice and C10 mouse epithelial cell culture supernatants,
and in C57Bl/6 mouse lung lavage fluid. MWCNT-induced HMGB1 secretion was
dependent upon caspase-1. HMGB1 increased MWCNT-induced IL-1β release from
macrophages in vitro, and neutralization of extracellular HMGB1 reduced MWCNTinduced IL-1β secretion in vivo. HMGB1 neutralization was accompanied with overall
decreased inflammation. In summary, this study suggests extracellular HMGB1
participates in NLRP3 inflammasome activity and regulates IL-1β associated sterile
inflammation induced by MWCNT.

Key Words: MWCNT, DAMP, IL-1β, sterile inflammation, caspase-1
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2.3. Background
MWCNT have remarkable physiochemical properties that will advance the fields of
medicine, electronics, and engineering. However, the high demand for these
materials, in concert with their toxicity potential, may pose a future health risk for
humans. Pulmonary exposure studies in murine models have revealed that MWCNT
exposure has negative consequences, including chronic inflammation leading to
granuloma formation and fibrosis, along with asthma-like pathology [4, 74, 7, 75-77].
The mechanisms that promote chronic inflammation are not clear, but activation of
the NLRP3 inflammasome in macrophages and IL-1β signaling has been shown to be
necessary for MWCNT-induced inflammation [4, 78, 79].
The NLRP3 Inflammasome is a multi-protein scaffolding complex that is
assembled in macrophages following MWCNT exposure. Assembly of the NLRP3
Inflammasome complex results in activation of caspase-1, which in turn, processes
pro-IL-1β and pro-IL-18 to their active, pyrogenic forms [80]. However, assembly of
the NLRP3 complex alone does not result in IL-1β secretion in vitro [81], for a signal
(often described as signal 1) is required for production of pro-IL-1β, usually
accomplished by adding low levels of endotoxin. This two hit method is widely used
to assess the inflammatory potential of particles in vitro. However, in mice kept in
SPF facilities treated with MWCNT or in conditions of sterile injury in humans,
endotoxin likely plays a minimal role, suggesting some other endogenous signal is
involved.
High Mobility Group Box 1 (HMGB1) is a nuclear architectural protein that is
secreted from injured/dead cells [82, 19, 83, 84], as well as actively secreted from
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cells of monocytic origin [17]. Secreted HMGB1 belongs to a large family of Danger
Associated Molecular Patterns (DAMPs) ligands, and has been implicated as an
activator of NF-κB in sterile inflammation. It has been reported that HMGB1 is
secreted via a non-conventional NLRP3 Inflammasome-mediated mechanism [18,
85]. Once outside the cell, HMGB1 has been shown to bind TLR4 and/or the
Receptor for Advanced Glycation End-products (RAGE) [86, 87], and through this
mechanism is suggested to mediate sepsis/LPS induced acute lung injury (ALI),
hemorrhagic shock, and ventilator-induced ALI [88-92]. HMGB1 has also been
identified as a mediator of bleomycin-induced fibrosis, likely through regulating the
severity of the acute inflammatory response [23]. Although HMGB1 has been shown
to play specific roles in these injury models, the secretory pathway of HMGB1 and
extracellular activity in MWCNT-induced inflammation, which has characteristics
distinct from other exposure models, is unknown. Additionally, whether HMGB1
contributes to NLRP3 Inflammasome-mediated inflammation following MWCNT
exposure, or whether other DAMPs are more critical to this activity, is not known.
The objective of this study was to elucidate the contribution of HMGB1 to
MWCNT-induced acute inflammation. Specifically, we hypothesized that HMGB1 has
the ability to regulate NLRP3 Inflammasome activity, and therefore, targeting
extracellular HMGB1 signaling or pathways that regulate HMGB1 secretion will be
mechanisms to decrease NLRP3 Inflammasome activity. In this study we assessed
for the presence and activity of HMGB1 following MWCNT exposure in vivo and in
vitro. The MWCNT used in this study has previously been shown to induce a robust
inflammatory and pathological response [78, 4]. The potential of extracellular HMGB1
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to act on primary AM is of particular focus in this study since previous findings report
strong correlations between AM production of IL-1β and pathology score following
MWCNT exposure [4]. Furthermore, caspase-1-/- mice were used to assess the
contribution of NLRP3 Inflammasome activation to HMGB1 secretion. Together, this
study describes a critical role for HMGB1 signaling in MWCNT-induced NLRP3
Inflammasome activity and associated inflammation.

2.4. Materials and Methods
2.4.1. MWCNT Preparation: The MWCNT selected for these studies, designated FA21 (Sun Innovations, Inc., Fremont, CA, USA; www.nanomaterialstore.com), was
selected due to its potent NLRP3 Inflammasome activity, and has been characterized
elsewhere [4]. This specific MWCNT is 1 of 24 samples provided by Dr. Nigel Walker
and Brad Collins at the National Toxicology Program (NTP) at the National Institute of
Environmental Health Sciences (NIEHS). Purity and metal content of the MWCNT
were determined using thermal gravimetric analysis (TGA) and x-ray fluorescence
spectrometry, respectively. Diameter and agglomeration state of the MWCNT were
determined by transmission electron microscopy (TEM) and dynamic light scattering
(DLS), respectively. This pro-inflammatory MWCNT has high nickel contamination
(approximately 5.54%), and forms agglomerates that range from 122 nm to 469 nm
depending on the dispersion media. Additionally, the MWCNT is free from endotoxin
contamination, a critical quality for investigating the sterile inflammatory response.
Prior to in vivo exposure by instillation or dispersion in vitro, MWCNT were
suspended in dispersion medium (DM, 0.6 mg/ml mouse serum albumin (Sigma-
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Aldrich, Saint Louis, MO) and 0.01 mg/ml 1,2-dipalmitoyl-sn-glycero- 3phosphocholine (Sigma-Aldrich) in PBS) and suspended using sonication for 1 min
[93].

2.4.2. Animals: C57Bl/6 and caspase-1-/- mice (2-month old) were housed in specific
pathogen free and controlled environmental conditions (22 ± 2°C; 30-40% humidity,
12 hr light, 12 hr dark cycle) and provided food and water ad libitum. All procedures
were performed under protocols approved by the IACUC of the University of
Montana.

2.4.3. Alveolar Macrophage isolation and culture: Mice were euthanized by sodium
pentobarbital (Euthasol™ Shering-Plough, Lot # 1JRR11V), and the lungs with the
heart were removed. After lavage, AM were isolated by centrifugation (400 x g, 5
min). Retrieved cells were counted using a Coulter Z2 particle counter (Beckman
Coulter, Miami, FL). AM were suspended in RPMI media supplemented with 10%
fetal bovine serum (FBS), sodium pyruvate, and supplemented with an
antimycotic/antibiotic cocktail (Mediatech, Manassas, VA). Cells were suspended at 1
x 106 cells/mL and exposed to MWCNT (25 ug/mL, 2.5 µg/105 cells) for 24 hr at 37°C
in a water-jacketed CO2 incubator (ThermoForma, Houston, TX) in a 96 well culture
plate. Recombinant HMGB1 (LPS free) was purchased from HMGBiotech. Cells were
exposed to LPS (10 ng/mL) or rHMGB1 (dose response: 0, 0.5, 1, 2 µg/mL) at the
same time as the MWCNT. rHMGB1 was formulated by the manufacture to be the
disulfide isoform, or cytokine active form [26, 22]. After 24 hours of culture with the

33

particle and treatment groups, supernatants were collected and assessed for
extracellular IL-1β and/or HMGB1.

2.4.4. C10 Cell Culture and Exposure: C10 epithelial cells, an immortalized nontransformed type II pneumocytic cell line cultured from BALB/c mice, were generously
provided by Dr. Galya Orr (Pacific Northwest National Laboratories, Richland, WA).
C10 cells were maintained in media identical to that used for AM. Cells were removed
by trypsinization for 5-10 min at 37°C, and plated at 80% density for 3 hours prior to
exposure to allow for adherence and acclimation. Cells were treated with MWCNT
(25 µg/mL) for 24 hr, after which the cell supernatants were collected, and debri
removed by centrifugation in order to assess extracellular HMGB1 levels by Western
Blot.

2.4.5. In vivo experiments: Mice were exposed to MWCNT (2 mg/Kg or 50 µg/25 g
mouse) by oropharyngeal aspiration [94]. Briefly, mice were anaesthetized using
isoflurane inhalation and the MWCNT prepared in DM were delivered into the back of
the throat while holding the tongue to the side, allowing for aspiration into the lungs.
For HMGB1 neutralization studies, mice were instilled with chicken anti-HMGB1 IgY
or Control IgY (Shinotest, Japan), or vehicle (PBS) only via oropharyngeal aspiration
1 hour following MWCNT instillations. After 1 day, the lungs were lavaged as
described with ice cold PBS (pH 7.4). AM were removed by centrifugation (400 x g, 5
min, 4°C) and cell counts obtained using the Coulter Z2 particle counter. Portions of
the cells were stained for differential analysis with Wright’s Giemsa stain using a
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Hematek 2000 autostainer (Miles-Bayer-Siemens Diagnostics, Deerfield, IL). The
acellular lavage was retained for assessment of IL-1β and HMGB1.

2.4.6. Assessment of endogenous HMGB1 in vitro: MWCNT or DM were instilled into
C57Bl/6 or caspase-1-/- mice as previously described and after 24 hours mice were
euthanized and lungs lavaged by instilling and retrieving 1 mL cold PBS repeatedly
(3x) to maximize concentration of extracellular HMGB1 in the lavage fluid. HMGB1
was either retained or removed from the lavage fluid by immunoprecipitation. Naïve
AM were isolated as described and exposed to MWCNT (25 µg/mL) in vitro and the
lung lavage fluid from MWCNT- or DM-treated mice with or without HMGB1. Prior to
treatment, lavage fluid was supplemented with 1% FCS to prevent AM starvation.
After 24 hours, supernatants were collected and assessed for IL-1β production.

2.4.7. HMGB1 immunoprecipitation and Western Blot Analysis: Protein A coated
magnetic Dynabeads® (Life Technologies) were prepared according to
manufacture’s instructions, and coated with 5 µg of anti-HMGB1 antibody (C-terminal
epitope, Sigma Aldrich). 1.5 mg of the bead/antibody conjugates were added to 1 mL
of the lavage fluid and incubated overnight at 4°C with gentle tumbling. HMGB1 was
then immunoprecipitated by magnetic separation, and the remaining lavage fluid and
immunoprecipitated product were assessed for the presence of HMGB1 by traditional
Western Blot analysis to confirm that HMGB1 had been successfully removed.
Briefly, 30 µL of sample including: cell supernatant, lavage fluid, or
immunoprecipitated HMGB1 was loaded on a 12-4% Bis-Tris polyacrylamide gel and
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run for 1 hour at 150 V. Protein was electrophoresed onto a PVDF membrane, and
blocked with 5% nonfat dry milk in Tris-buffered saline. After blocking, the membrane
was incubated overnight at 4°C with anti-HMGB1 antibody (1:1000), washed 3 times,
and then detected using a donkey anti-rabbit horseradish peroxidase-coupled
secondary antibody (1:10,000). After washing 3 more times, the blot was developed
using Fempto™ chemo-luminescence detection reagents (Pierce, Thermo Scientific,
Rockford, IL).

2.4.8. HMGB1 Assay: HMGB1 was measured by ELISA using commercially available
antibodies (R&D Systems, Minneapolis MN; EMD Millipore, Billerica, MA, Santa-Cruz
Biotech, Dallas, TX) and previously validated protocols [95, 96]. Slight adjustments
were made to these protocols, including decreased blocking time (2 hours) in 4%
BSA in PBS, 2 hours of sample incubation with the primary antibody, followed by a 2
hour detection antibody incubation. ELISA specificity was confirmed by Western Blot.
Lavage samples were run immediately on the ELISA in order to remove variability
and potential degradation caused by freeze-thaw.

2.4.9. Cytokine Assays: IL-1β and TNF-α were measured using mouse Duo-Set
ELISA (R&D Systems, Minneapolis, MN) following the manufacture’s protocol. Total
Protein was measured using the BCA assay (Pierce, Thermo Scientific, Rockford, IL).

2.4.10. Statistical Analysis: Statistical analyses involved comparison of means using
a one or two-way ANOVA followed by Dunnett’s test or Bonferroni’s test to
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compensate for increased type I error. All probabilities were two-tailed unless
otherwise stated. Statistical power was greater than 0.8. Statistical significance was
defined as a probability of type I error occurring at less than 5% (P < 0.05). The
minimum number of experimental replications was 3. Graphics and analyses were
performed on PRISM 5.0.

2.5. Results
2.5.1. MWCNT exposure increases extracellular HMGB1 levels: The ability of
MWCNT to induce HMGB1 secretion was assessed by instilling C57Bl/6 (WT) mice
with 50 µg/mouse (2 mg/kg) of particle or DM, and after 24 hours, mice lungs were
lavaged and HMGB1 concentrations were measured in the lavage fluid by ELISA.
The MWCNT dose used for the in vivo studies was selected based on prior results
showing it was the lowest amount required for reproducible measurements of IL-1β
dependent inflammation and pathology [78]. The physiochemical characteristics and
NLRP3 Inflammasome activating potential of the MWCNT used in these studies has
been previously reported [4]. MWCNT exposure increased HMGB1 in the lung lavage
fluid (Figure 1A). In order to assess potential sources of HMGB1 following MWCNT
exposure in the lung, isolated primary AM and C10 cells were treated with 25 µg/mL
MWCNT and extracellular HMGB1 concentrations were assessed after 24 hr. The
dosage chosen for in vitro studies was selected to eliminate interference of the
particle in colorimetric/fluorescent assays that occurs at higher doses, and yet this
lower dose retains the ability to induce a significant IL-1β response. MWCNT
exposure resulted in increased extracellular HMGB1 in C10 cell supernatant (Figure
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1B). Likewise, MWCNT exposure induced a non-significant increase of extracellular
HMGB1 in AM supernatants, which was significantly enhanced by stimulation with
low levels of LPS (Figure 1C). C10 cells are susceptible to MWCNT cytotoxicity, as
measured by the LDH assay [45]. Similarly, MWCNT are cytotoxic to AM [4],
suggesting that passive release is a likely source of part of the extracellular HMGB1
pool. Endotoxin stimulated enhancement of HMGB1 secretion in AM also suggests
that there is active secretion as well. Together, the data in Figure 1 demonstrate
MWCNT induce HMGB1 secretion in the lung, and both epithelial and AM are
plausible sources of HMGB1 through passive and active secretion.

2.5.2. HMGB1 secretion is dependent on caspase-1: The NLRP3 Inflammasome
activates caspase-1, which in turn facilitates pro-IL-1β processing and secretion.
Reports suggest that HMGB1 secretion is dependent upon NLRP3 Inflammasome
activation of caspase-1 [18, 85]. However, the dependence of HMGB1 secretion on
caspase-1 has not been evaluated with nanoparticles such as MWCNT. Therefore,
we instilled caspase-1-/- mice with MWCNT or DM, and after 24 hours, assessed
HMGB1 concentrations in whole lung lavage fluid. Caspase-1-/- mice had significantly
less HMGB1 than WT (Figure 1A), confirming that HMGB1 secretion is dependent
upon caspase-1 in MWCNT exposure models.

2.5.3. Native HMGB1, but not rHMGB1, contributes to signal 1 of NLRP3
Inflammasome Activation: The contribution of HMGB1 to particle-induced
inflammatory response, specifically the ability of HMGB1 to act as signal 1, has not
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been investigated. To elucidate whether HMGB1 can act as the NF-κB activating
signal in vitro, primary AM were exposed to MWCNT and a dose response of
commercially available disulfide form rHMGB1, reported to have NF-κB activating
function [26, 22]. rHMGB1 failed to induce IL-1β secretion at any dose in primary AM
(high dose shown, Figure 2A), as well as in two other macrophage-like cell models,
including: THP-1 and Bone Marrow derived Macrophages (Supplementary Material:
S1A, S1B). Likewise, TNF-α was not increased in any of these models (data not
shown). Specific HMGB1 isoforms have been identified to contribute more to different
disease models, and the rHMGB1 used in this proposal, which has been reported to
signal through TLR4 [26], may not be comparable to endogenous HMGB1 in the lung
following MWCNT exposure. To elucidate the ability of endogenous, native HMGB1
(nHMGB1) to act as signal 1, primary AM were isolated from C57Bl/6 and exposed to
MWCNT in vitro, then treated with cell free lung lavage fluid obtained from DM or
MWCNT-exposed mice (24 hour exposure period in vivo before isolation of cell free
lung lavage fluid). In parallel, a second group of MWCNT-exposed C57Bl/6 AM was
treated with lung lavage fluid from DM or MWCNT-exposed mice, where HMGB1 had
been removed by immunoprecipitation (Figure 2C). Treatment with lung lavage fluid
from MWCNT-treated mice enhanced IL-1β secretion in MWCNT-exposed AM,
demonstrating that an endogenous signal 1 is present and soluble in the lung lavage
fluid of MWCNT- treated mice (Figure 2B). Removal of HMGB1 by
immunoprecipiation from the lung lavage fluid prior to treatment resulted in
significantly less IL-1β production from MWCNT-exposed AM, indicating that HMGB1
is that endogenous signal 1 following MWCNT exposure. Immuno-blotting and
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Coomassie blue staining revealed that the majority of immunoprecipitated protein
was HMGB1 (Supplementary Material, S2). Similar experiments were performed in
which C57Bl/6 AM were exposed to MWCNT with lavage fluid from caspase-1-/- mice.
Lavage fluid isolated from caspase-1-/- mice exposed to MWCNT failed to induce IL1β secretion from C57Bl/6 AM exposed to MWCNT in vitro (data not shown),
supporting the reported role of caspase-1 in HMGB1 secretion and signaling.

2.5.4. HMGB1 neutralization decreases IL-1β release in vivo: To translate the
contribution of HMGB1 to NLRP3 Inflammasome activity in vivo, mice were
administered HMGB1 neutralizing antibodies or control IgY antibodies by
oropharyngeal aspiration 1 hr following MWCNT instillation. HMGB1 neutralization
significantly decreased IL-1β levels in the lung lavage fluid at 1 day (Figure 3A), along
with decreased inflammatory markers including neutrophil (trending but nonsignificant), and eosinophil counts (Figure 3C, 3D). Additionally, there was a nonsignificant, but trended decrease in total protein and TNF-α, (Supplementary Material:
S3A, S3B). However, HMGB1 neutralization did not decrease total cell counts (Figure
3B). Treatment with the isotype control and anti-HMGB1 antibodies induced an
increase in neutrophils vs. vehicle only (data not shown), however this had no effect
on IL-1β levels, and appeared to be non-inflammatory. Despite the increase in
neutrophil numbers with antibody instillation, the anti-inflammatory trends of HMGB1
neutralization remained consistent. Together, this data supports a specific role for
extracellular HMGB1 in mediating NLRP3 inflammasome activity, specifically the
secretion of IL-1β, in vivo. Furthermore, this data suggests an important role for
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HMGB1/ IL-1β dependent recruitment of eosinophils in C57Bl/6 mice exposed to
MWCNT.

2.5.5. Caspase-1-/- mice have decreased NLRP3 inflammasome activity: MWCNT
exposure in caspase-1-/- mice resulted in decreased IL-1β release, along with other
standard inflammatory parameters including: total cell count and neutrophil counts
(Figure 4A, 4B, 4C). This data supports the critical role of caspase-1 processing of IL1β and HMGB1 signaling in MWCNT-induced inflammation. However, MWCNTexposed caspase-1-/- mice retained similar levels of eosinophil recruitment compared
to WT control (Figure 4D). This suggests that despite decreased HMGB1 levels in
the lavage fluid, caspase-1-/- mice have a compensating, HMGB1 independent
pathway for recruitment of eosinophils.

2.6. Discussion
Due to the diversity of physiochemical properties and potential modifications of
MWCNT, in vitro screening of inflammatory potential will be critical to identifying their
potential to cause lung disease. Past studies by our laboratory have demonstrated
that MWCNT physiochemical properties that promote more lL-1β secretion also result
in greater pathology [4, 7]. This assessment currently requires stimulation of
macrophages with endotoxin, a practice widespread when assessing inflammasome
activation by inhaled particles. Pre-sensitization to LPS has been shown to enhance
MWCNT-induced inflammation and fibrosis, and LPS has been shown to be a major
contributor to environmental particle induced lung disease by integrating with the

41

hazardous material in the environment [97, 98]. However, it is important to consider
the sterile nature of MWCNT-induced inflammation in vivo. The MWCNT used in
these studies were free from LPS contamination, primarily due to the manufacturing
process that requires high temperatures and controlled conditions. The mice used in
these studies were kept in SPF conditions, where the contribution of LPS to NLRP3
Inflammasome activity is not evident. The “danger theory” of the inflammatory
response indicates that sterile injury is sufficient for NLRP3 inflammasome activation
and associated disease through the release of endogenous DAMPs, including
HMGB1 [99]. The current two hit hypothesis for MWCNT in vitro activation includes
MWCNT activation of the NLRP3 Inflammasome through lysosomal membrane
permeablization [4], and the activation of NF-kB by an endogenous DAMP (see
Figure 5).
Results from this study implicate that HMGB1 plays an integral role in sterile
activation of the NLRP3 Inflammasome. The contribution of HMGB1 to sterile
inflammation has been of recent interest due to its ability to bind TLR4/RAGE leading
to NF-κB activation [86, 87]. While most studies on HMGB1-mediated inflammasome
activity have been done following exposure to high levels of endotoxin, bleomycin, or
mechanical stress [23, 92, 88], the contribution of HMGB1 to MWCNT-induced
inflammation and disease has not hitherto been elucidated. Not only did MWCNT
exposure elevate levels of HMGB1, but also we confirmed native HMGB1
participated in NLRP3 inflammasome activation.
HMGB1 secretion has been observed to be through both active (from
monocytic cells) and passive mechanisms (secondary to necrosis or apoptosis) [17,
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82, 19, 85]. Increased cytotoxicity has been observed with MWCNT exposure in
epithelial cells and AM [45, 4], however the pre-dominant form of MWCNT-induced
cell death is conflicting, and likely depends upon particle physiochemical and surface
properties. However, increased HMGB1 secretion from primary AM exposed to LPS
and MWCNT, along with decreased secretion from Caspase-1-/- mice, suggests that a
portion of the extracellular HMGB1 present following MWCNT exposure is processed
through an active caspase-1 mediated secretory mechanism. Higher levels of LPS
than those used in this proposal have been shown to induce HMGB1 translocation
from the nucleus to the cytosol, where it is then secreted, like IL-1β, through an
unconventional pathway [17]. The observation that HMGB1 secretion was dependent
on caspase-1 activation suggests that the NLRP3 Inflammasome is integral to the
secretory pathway, and is not limited to processing of cytokine precursors.
Others have reported that specific HMGB1 isoforms are required for proinflammatory, cytokine-like function or chemokine activity. Specifically, a disulfide
bridge between cysteine residues 23 and 45, along with a reduced cysteine residue
at 106, constitutes HMGB1 with cytokine-like activity [26, 22, 100]. Fully reduced
HMGB1 is considered to be primarily chemotactic. The failure of the disulfide
rHMGB1 isoform to act as signal 1 in our model suggests that the endogenous form
in the lung, following MWCNT exposure, is distinct from the commercial product.
Though most of the HMGB1 immunoprecipitated in these studies was soluble (Figure
2C), it is possible that there was co-immunoprecipiation of immune complexes
present at low levels with greater specificity to activate NF-κB, that were not detected
due to the insensitive nature of coomassie blue. Others have demonstrated HMGB1
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binds to IL-1β, LPS, and extracellular DNA in situ, and that these complexes have
increased immune-stimulatory activity [101, 102]. Alternatively, since HMGB1
secretion is dependent upon caspase-1, it is possible that HMGB1 is targeted by
caspase-1 prior to secretion, and that this cleaved isoform is important in extracellular
signaling. However, HMGB1 targeting by caspase-1 has had conflicting reports and
was not assessed in these studies [103, 18]. Furthermore, the integration of the
NLRP3 Inflammasome into the unconventional secretory pathway may be a pathway
around direct caspase-1 cleavage of HMGB1 [104].
IL-1β signaling has been shown to be a significant contributor to neutrophil and
eosinophil recruitment after MWCNT exposure [78]. IL-1R null mice have decreased
eosinophil and neutrophil recruitment 24 hours after MWCNT exposure. Likewise
HMGB1 neutralization in this study, resulting in decreased IL-1β, resulted in
decreased eosinophil counts and a decreasing trend in neutrophil recruitment.
Similarly, HMGB1 neutralization has been reported to decrease eosinophil
recruitment in a murine asthma model using Ova/Albumin sensitization [105]. The
mechanism for HMGB1 recruitment of eosinophil and neutrophils remains to be
defined, though general cell migration towards HMGB1 has been reported to be
dependent on CXCL12 and sustained NF-κB activation [106].
We present a conceptual model for the role of extracellular HMGB1 activity in
MWCNT-induced inflammation in Figure 5. This study demonstrates extracellular
HMGB1 in MWCNT exposure regulates NLRP3 inflammasome activity by
participating in the NF-κB activating step. Though HMGB1 neutralization results in
reduced acute NLRP3 Inflammasome activity, the dependence of MWCNT-induced
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long-term pathology on HMGB1 remains to be determined. It is plausible that HMGB1
functions as part of the NF-κB activating signal in many other models of particle
exposure, which require NLRP3 Inflammasome activity. Therefore, assessment of
MWCNT bioactivity (including NLRP3 inflammasome activity) should include
measuring the ability of MWCNT and other particles to induce HMGB1 secretion.

2.7. Conclusions
These studies establish extracellular HMGB1 as a regulator of NLRP3 inflammasome
activity in vivo following MWCNT exposure. HMGB1 secretion is dependent upon
caspase-1, and this study provides evidence that targeting HMGB1 signaling through
extracellular neutralization or secretion pathways (caspase-1 dependent) may have
therapeutic implications, however, further studies are needed. Finally, the potency of
MWCNT to induce HMGB1 secretion should be considered in future studies
delineating inflammatory potential of MWCNT and conceivably other inhaled
particulates that act through a similar mechanism.
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Figure 2.1. HMGB1 levels following MWCNT exposure in vitro and in vivo. (A)
HMGB1 levels in whole lung lavage fluid 24 hr following MWCNT (50 µg/mouse) or
DM instillation in C57Bl/6 or caspase-1-/- null mice. HMGB1 levels were assessed in
sham (non-instilled mice) to assess injury caused by instillation of the vehicle. (B)
Extracellular HMGB1 detected in C10 cell supernatants following 24 hours of
exposure to MWCNT (25 µg/mL). (C) HMGB1 levels in primary AM cell supernatant
24 hours following MWCNT (25 µg/mL) exposure with (black bar) or without (white
bar) LPS (10 ng/mL). *p<0.05, **p<0.01
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Figure 2: Naive alveolar macrophages were exposed to dispersion
medium (DM, white bar) or MWCNT (black bar) in vitro for 3 hours to
ensure particle uptake and inflammasome assembly. Macrophages were
then incubated for 24 hours in lavage fluid collected from mice 24 hours
after instillations with DM. Macrophages were also incubated in lavage
where HMGB1 was depleted by immunoprecipitation (B). Lavage fluid
was supplemented with 1% FCS to maintain macrophage viability. Cell
supernatants were analyzed for IL-1! by ELISA. (Data represent mean
values +/- SEM, ***P<.001)

Figure 2.2. nHMGB1 not rHMGB1 participates in inflammasome activity in vitro. (A)
IL-1β in primary AM cell supernatants 24 hr following MWCNT exposure and

treatment with either LPS (10 ng/mL) or rHMGB1 (2 µg/mL). (B) IL-1β in primary AM
cell supernatants after 24 hr exposure to MWCNT (black bar, 25 µg/mL) in vitro, and
exposure to cell free lung lavage fluid from DM-exposed mice (DM LLF) or MWCNTexposed mice (MWCNT LLF). nHMGB1 was immunoprecipitated out of the lavage
fluid to form treatment groups DM LLF (- HMGB1) and MWCNT LLF (-HMGB1). (C)
Representative Western Blot confirming that nHMGB1 was removed from the lung
lavage fluid prior to addition to primary AM in vitro. **p<0.01. ***p<0.001.
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Figure 2.3. Neutralization of HMGB1 decreases IL-1β secretion and associated
inflammation. (A) IL-1β concentration in lung lavage fluid 1 day following MWCNT
instillation and treatment with HMGB1 neutralizing antibodies or control antibodies,
(B) Total cell counts, (C) Neutrophil counts, and (D) Eosinophil counts in the lung
lavage fluid 1 day following treatment MWCNT treatment and administration of
antibodies. *p<0.01. **p<0.01. ***p<0.001.
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*p<0.01, ***p<0.001.
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Figure 2.5. Model depicts the contribution of HMGB1 to MWCNT-induced
inflammation. Macrophages phagocytose MWCNT (signal 2), which induce lysosomal
membrane permeablization (LMP), leading to activation of the NLRP3 Inflammasome
and caspase-1. Signal 1 is required for activation of NF-κB, which is accomplished by
activation of a DAMP recognition receptor such as RAGE or TLR4. HMGB1 is
released passively by injured cells or by active secretion from macrophages, and
participates in Signal 1.
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Supplementary Figure 2.6. rHMGB1 with MWCNT exposure fails to induce
inflammasome activity in THP-1 and Bone Marrow derived Macrophages (BMdM). (A)
Differentiated THP-1 were exposed to MWCNT (25 µg/mL) and either LPS (10
ng/mL) or a dose response of rHMGB1 (0.5, 1.0, 2.0 µg/mL). (B) Repeated study in
BMdM. IL-1β was assessed by ELISA in the cell supernatants after 24 hr.
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Supplementary Figure 2.7. Representative Blot (n=3) of coomassie blue staining of
immunoprecipitated HMGB1. Lane 1) molecular mass ruler. 2) Control Cell lysate for
identification of HMGB1. 3) Immunoprecipitated HMGB1 from lavage fluid of MWCNT
treated mice 24 hr after instillation. 4) Immunoprecipitated HMGB1 from mice treated
with DM 24 hr after instillation. 5) Lavage fluid from MWCNT mice after
immunoprecipitation of HMGB1. 6) Lavage fluid from DM mice after
immunoprecipitation of HMGB1.
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by ELISA. Total Protein concentration was assessed by the BCA assay.

54

CHAPTER 3: PHAGOLYSOSOME ACIDIFICATION IS NECESSARY FOR SILICA
AND ENGINEERED NANOPARTICLE-INDUCED MEMBRANE
PERMEABILIZATION AND RESULTANT NLRP3 INFLAMMASOME ACTIVITY

3.0. Manuscript Information Page
Authors: Forrest C Jessop1†, Raymond F. Hamilton1, Joseph F. Rhoderick 1, Paige
Fletcher1 and Andrij Holian1

Target Journal: Journal of Biological Chemistry

Status of Manuscript:
___ Prepared for submission to a peer-reviewed journal
_X_ Officially submitted to a peer-review journal
___ Accepted by a peer-review journal
___ Published in a peer review journal

Published by American Society for Biochemistry and Molecular Biology
Submitted May, 2016

55

3.1. Phagolysosome acidification is necessary for silica and engineered
nanoparticle-induced membrane permeabilization and resultant NLRP3
inflammasome activity

Forrest Jessop*1, Raymond F. Hamilton Jr*, Joseph F. Rhoderick*, Paige Fletcher*
and Andrij Holian*

*Center for Environmental Health Sciences, Department of Biomedical and
Pharmaceutical Sciences, University of Montana, Missoula, Montana

Correspondence author1

56

3.2. Abstract
NLRP3 inflammasome activation occurs in response to multiple particles including
crystalline silica, engineered nanomaterial Multi-Walled Carbon Nanotubes
(MWCNT), and Titanium Nanobelts (TNB). NLRP3 inflammasome activity is critical
for the development of disease. However, mechanisms that drive persistent NLRP3
inflammasome activity are not fully understood. In this study we investigated the
contribution of lysosome membrane permeabilization (LMP) and associated
cathepsin B release in the context of silica and nanoparticle-induced NLRP3
inflammasome activity. We demonstrate that silica, MWCNT, and TNB cause
significant LMP in Bone Marrow derived Macrophages in vitro. Particle-induced LMP
was prevented with Bafilomycin A1, an inhibitor of phagolysosome acidification. LMP
was also evident in alveolar macrophages in vivo 7 d following particle exposure.
Cytosolic cathepsin B activity, which occurs following LMP, was responsible for
causing NLRP3 inflammasome activity in vitro and NLRP3 inflammasome activity
persistence in vivo. Active cathepsin B regulated both the activation of cathepsin L
and the secretion of the alarmin HMGB1 with particle exposure. Together, these data
highlight the necessity of phagolysosome acidification in particle-induced LMP.
Furthermore they support an NLRP3 inflammasome dependent mechanism that
includes active cathepsins in the secretion of HMGB1 with particle exposure.

Key Words: NLRP3 inflammasome, MWCNT, TNB, Silica, Lysosome Membrane
Permeabilization
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3.3. Background
Silica was one of the first environmental particles identified to activate the
NLRP3 inflammasome [16]. It is now known that many particles, both exogenous and
endogenous, environmental and engineered, of many sizes and shapes, are
activators of the NLRP3 inflammasome, making inflammasome activity and
associated signaling pathways a common target for next generation therapeutics.
Gene knockout studies of inflammasome components NLRP3 and caspase-1 in
murine models have shown diminished particle-induced acute inflammation and/or
fibrosis [107-109]. With the rapid expanding market of engineered nanomaterial
(ENM), there is cause for concern as many of these particles, like silica, could
potentially cause chronic inflammatory disease. Therefore, there is a serious need to
characterize the inflammation-inducing, or bioactive, potential of ENM.
Inhaled particles are phagocytosed by alveolar macrophages, and the
phagosome containing particle(s) matures and fuses with lysosomes to attempt to
degrade the particle. Most inorganic environmental particles such as silica, and many
ENM are resistant to degradation, and consequently, their fate in the phagolysosome
is not fully understood. Phagocytized silica particles induce lysosome membrane
permeabilization (LMP) resulting in NLRP3 inflammasome assembly [107, 16].
NLRP3 inflammasome assembly results in activation of caspase-1, which cleaves the
pro-forms and mediates the secretion of pyrogenic cytokines IL-1β and IL-18, which
are central to the development of chronic inflammatory lung diseases [110]. Prior
studies provide data consistent with ENM-induced LMP and NLRP3 inflammasome
activation, however these studies do not specifically quantify LMP or address
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mechanisms by which particles cause LMP [111, 5, 112]. Consequently, the
mechanisms responsible for LMP and magnitude of LMP caused by bioactive particle
exposure require further investigation.
Active lysosomal proteases and low pH are reported to be necessary for
removal of protein corona’s on nanomaterial [113], which may allow for direct particlemembrane interactions. Critical to phagosome acidification are recruitment and
activation of lysosomal vATPases. In addition, optimal activation of lysosomal
proteases, such as cathepsin B, requires a low pH environment [114].
Phagolysosome acidification has been reported to play a role in LMP following
treatment with Leu-Leu-OMe [16], likely through decreased Dipeptide Peptidase I
(cathepsin C) activity, which processes the agent to its active form [115].
Phagolysosome acidification is suspected to play a role in LMP with silica exposure
due to its ability to decrease downstream NLRP3 inflammasome activity [16].
Whether Bafilomycin A1 inhibition of NLRP3 inflammasome activity with silica
exposure is due to direct inhibition of LMP or inhibition of the activation of cathepsin B
is not known. Therefore, the contribution of phagolysosome acidification to silica and
nanoparticle-induced LMP remains to be determined. Some reports suggest that
active lysosomal protease cathepsin B may directly participate in causing LMP [116,
117, 54, 55]. Once leaked from the lysosome, cathepsin B facilitates NLRP3
inflammasome activation [16]. This is reported to be the case for certain ENM as well
[111].
LMP occurs within hours in macrophages following bioactive particle exposure
[16]. The persistence of LMP following bioactive particle exposure has not hitherto
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been investigated in vivo. Evidence of LMP in vivo is sparse, let alone in models in
which particles are responsible for LMP. The objective of this study was to determine
common mechanisms contributing to particle-induced LMP and NLRP3
inflammasome activity with silica and bioactive nanoparticle exposure. We
hypothesized that LMP would drive persistent NLRP3 inflammasome activity in vivo
with particle exposure. Furthermore, we hypothesized that lysosome acidification is
necessary for silica and ENM-induced LMP. Multiple particles including silica, MultiWalled Carbon Nanotubes (MWCNT), Titanium Nanobelts (TNB), and Titanium
Nanospheres (TNS) were used in these studies to assess commonality of LMP to
persistant NLRP3 inflammasome activity with particle exposure. Further
characterizing mechanisms by which LMP occurs and the persistence of LMP
following exposure will be necessary to understand dynamics governing chronic
NLRP3 inflammasome activity.

3.4. Materials and Methods
3.4.1. Particle Characteristics and Preparation
All particles used in these studies have been previously described, in which LPS
contamination was determined to be negligible by the Limulus amebocyte lysate
assay (Cambrex, Walkersville, MD, USA) [12, 118, 111, 5, 119]. Acid washed
crystalline silica (Pennsylvania Glass Sand Corp, Pittsburgh, PA, USA) with average
particle size 1.5 – 2 µm was prepared fresh in phosphate-buffered saline (PBS, pH
7.4) and sonicated (550 watts @ 20 kHz) for 1 min in a cup-horn sonicator (Misonix,
Inc. Farmingdale, NY, USA) prior to use. MWCNT (Sun Innovations, Inc., Fremont
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CA, USA. www.nanomaterialstore.com) was prepared fresh in dispersion medium
(DM, 0.6 mg/mL mouse serum albumin (Sigma-Aldrich, Saint Louis, MO, USA) and
0.01 mg/mL 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (Sigma-Aldrich) in PBS)
and sonicated (550 watts @ 20 kHz) for 1 min in a cup-horn sonicator [120]. MWCNT
were provided by Dr. Nigel Walker and Brad Collins at the National Toxicology
Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS).
TNB and TNS were prepared and provided by Dr. Nianqiang Wu at West Virginia
University (Morgantown, WV, USA) and have been characterized extensively [5,
120]. TNB and TNS were suspended in PBS using a stir bar for 1 hr due to potential
fracture by sonication [119].

3.4.2. Mice
Both male and female C57Bl/6 and caspase-1 null mice (Jackson Laboratories, Bar
Harbor, ME, USA) were used in equal numbers for all studies. Animals were housed
in micro-isolators in a specific pathogen-free facility under a 12:12-hr light-dark cycle.
Food, bedding, and cages were sterilized by autoclaving. Mice were used between
8-12 wk of age. The University of Montana Institutional Animal Care and Use
Committee (Missoula, MT, USA) approved all procedures performed on the animals.

3.4.3. Bone Marrow derived Macrophages
BMdM were obtained as described previously [30]. Briefly, wild-type C57Bl/6 were
sacrificed and bone marrow was flushed from the isolated femur and tibia with media.
Cells were then incubated in T75 culture flasks (20 mL RPMI + 10%FCS) overnight
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for stromal cell elimination. Aspirated cells were transferred to new T75 flasks
(15x106 cells/flask in 20 mL media) and 40 µL macrophage colony stimulating factor
(M-CSF) added (10 ng/mL stock, R&D Systems). Cultures continued for 7–10 days
with re-feeding and M-CSF spiking every 3–4 days.

3.4.4. In vitro studies
BMdM were plated in a 96 well plate (1x105 cells/well) and exposed to particles and
LPS (20 ng/mL) for inflammasome priming. Cells were treated with/without the
cathepsin B inhibitor CA-074-Me (10 µM, Peptides International, Louisville, KY, USA)
or Bafilomycin A1 (100 nM, EnzoLife Sciences, Farmingdale, NY, USA) and cell
supernatants collected after 24 hours. Cell supernatants were assessed for IL-1β
and IL-18 cytokine levels by ELISA (R&D Systems, Minneapolis, MN, USA). IL-18
was measured by an in-house ELISA previously described [6].

3.4.5. In vivo and ex vivo studies
Mice were anaesthetized using isoflurane inhalation and then exposed to silica (40
mg/kg or 1 mg/25 g mouse) or MWCNT, TNB or TNS at 2 mg/kg (50 µg/25 g mouse),
by oropharyngeal aspiration [121]. The doses used for these studies were selected
based on their inflammatory activity established in prior work [12, 118, 111, 5]. Mice
were lavaged after 7 d for analysis of inflammation and LMP. For chronic studies,
mice were instilled once a week with silica for 4 consecutive weeks and sacrificed 56
d following the first instillation [12]. Alveolar Macrophages (AM) were isolated from
the lavage fluid from both the early (7 d) and chronic time points (56 d) and cultured
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ex vivo in RPMI + 10% FCS for 24 hr with or without LPS (20 ng/mL) and the
cathepsin B inhibitor CA-074-Me (10 µM). Cell supernatants and cell free lavage were
assessed for IL-1β and IL-18 by ELISA as previously described. HMGB1 was
measured by ELISA using commercially available antibodies (R&D Systems; EMD
Millipore, Billerica, MA, USA; Santa-Cruz Biotech, Dallas, TX, USA) as previously
described [122]. Whole lung lavage fluid was also assessed for LDH activity
(Promega, Madison, WI, USA) and protein content using the BCA assay (Thermo
Fisher Scientific, Waltham, MA, USA). Extracellular cathepsin activity was assessed
as previously described by our laboratory [123]. Briefly, 2 µg Z-LR-AMC (specific to
cathepsin B, cathepsin L and cathepsin V; R&D systems) in PBS was added to 50 µL
of whole lung lavage fluid in a total reaction volume of 150 µL. The assays were
incubated at 37°C for 1 h then fluorescence was measured using a plate reader at
380 nm excitation and 460 nm emission.

3.4.6. Lysosome Membrane Permeabilization (LMP) assay
LMP was assessed using methods modified from Aites et al [60]. Isolated AM were
plated in a 96 well plate at 1 x 105 cells per well and allowed to adhere for 2 hours.
For BMdM, cells were plated at 2 x 105 cells per well in a 24 well plate. Cells were
washed twice with PBS to remove dead cells and debris. AM or BMdM were then
incubated with 100 µL (96 well) or 200 µL (24 well) of cytosol extraction buffer (250
mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
0.5 mM pefabloc (Sigma-Aldrich), pH 7.5 + digitonin (Sigma-Aldrich)) for 15 min on
ice with rocking. The concentration of digitonin for optimal extraction of the cytosolic
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fraction was obtained by titration (BMdM = 12.5 µg/mL; AM = 17.5 µg/mL). 50 µL of
extracted cytosol was then added to 50 µL of cathepsin reaction buffer (50 mM
sodium acetate, 4 mM EDTA, pH 6.0 + fresh 0.5 mM pefabloc, 8 mM DTT, 50 µM
cathepsin L substrate (Z-Phe-Arg-AFC, EnzoLife Sciences)) and read using a plate
reader (25 min; 45s intervals; 400 nm excitation; 489 nm emission). β−N-acetylglucosaminidase (NAG) activity was measured by adding 30 µL cytosolic extract to
100 µL of NAG reaction buffer (0.2 M sodium citrate, pH 4.5 with 300 µg/mL 4methylumbelliferyl-2-acetamido-2-deoxy-β-D-glucopyranoside (Sigma-Aldrich)) and
assessed on a plate reader (20 min; 45s intervals; 356 nm excitation; 444 nm
emission). LDH activity was assessed following manufactures instructions (Promega).
Extracted cytosolic LDH activity was used as an internal control to which cytosolic
cathepsin L or NAG activities were normalized. Cytosolic extract enzyme activities
were calculated as a percent of total cell lysate activity in which 200 µg/mL of
digitonin was used to completely lyse the cell.

3.4.7. RNA preparation and RT-PCR
Isolated AM (4 mice pooled for each N) from mice 7 d following PBS or silica
exposure were lysed and total RNA isolated in Trizol (Thermo Fisher Scientific). The
RNA Integrity Number (RIN) and total RNA concentration was confirmed using the
RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA, USA) and Agilent
Bioanalyzer 2000. Prior to cDNA synthesis, 100 ng of total RNA was treated with 12U of DNAse I (Quanta Biosciences, Gaithersburg, MD, USA). All RNA samples were
reverse transcribed using iScript Reverse Transcription Supermix (BioRad, Hercules,
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CA, USA) in accordance with the manufacturers protocol. PrimeTime qPCR primers
to Caspase-1 (Casp1, Prime Time Assay Mm.PT.58.13005595), IL-1β (Il-1b,
Mm.PT.58.42940223), NLRP3 (Nlrp3, Mm.PT.58.42443451), ASC (Pycard,
Mm.PT.56a.42872867), and reference genes Adck1 (Mm.PT.56a.41787370) and
Pigo (Mm.PT.58.6147472) were used for RT-PCR reactions (IDT, Coralville, IA,
USA). Efficiency for PrimeTime primers was established via standard curve analysis
of at least two biological replicates using cDNA synthesized from AM or genomic
DNA isolated from murine lung tissue respectively. Efficiencies for all primer pairs
used in PCR analysis >89%. All signals were normalized to Adck1 and Pigo and
relative expression levels determined using the REST 2009 v2.0.13 software suite
(Qiagen, Valencia, CA, USA).

3.4.8. Western Blot
Isolated cells obtained from lung lavage fluid were lysed directly in RIPA buffer
containing HALTTM protease inhibitors (Life Technologies, Carlsbad, CA, USA).
Whole lung lavage cells from 4 mice were pooled for each N. Lysates were run on 412% Bis-Tris SDS-PAGE gels. Anti-NLRP3 antibodies were obtained from R&D
Systems. Anti-ASC, Anti-caspase-1, and anti-pro-IL-1β antibodies were obtained
from Novus Biologicals (Littleton, CO, USA). The secondary antibodies were donkey
anti-rabbit conjugated to horseradish peroxidase (BioLegend, San Diego, CA, USA).

3.4.9. Detection of Cathepsin B and LysotrackerTM Red
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Cathepsin B and lysosomes were measured using a CompuCyte iCys Laser
Scanning Cytometer (LSC, Westwood, MA, USA). Briefly isolated lung lavage cells
were seeded in triplicate wells in a 96-well plate with a glass coverslip bottom
(MatTeck Corp. Ashland, MA, USA) at 1 x 105 cells/well. Non-adherent cells were
removed by gentle washing once with PBS. Cells were then stained using the Magic
RedTM Cathepsin B Detection Kit (ImmunoChemistry Technologies, Bloomington, MN,
USA) or LysoTracker Red DND-99 dye (Life Technologies) and counter-stained with
Molecular Probes HCS NuclearMask Blue stain (Life Technologies) according to
manufacture’s instructions. The cathepsin B signal or Lysotracker Red signal was
detected using a 561 nm laser as the excitation source and a PMT detector with a
600/50 nm bandpass filter. The nuclear staining was excited with a 405 nm laser and
detected with a 440/30 nm bandpass filter/PMT set. Individual passes of the 561 nm
and 405 nm lasers were used to avoid any spectral overlap of the “blue” and “red”
fluorescent signals. A threshold of “blue” fluorescence was set such that the software
draws a contour around the nucleus of the cell. The contour is then expanded by 20
pixels to include the cytoplasm of the cell. Each cell (defined by nuclear staining) is
plotted on a histogram showing Red Mean Fluorescent Intensity (MFI). Regions were
defined within each well of the 96-well plate to include approximately 1500 cells to
achieve sufficient sample representation.

3.4.10. Statistical analysis
Statistical analyses involved comparison of means using a one- or two-way ANOVA
followed by a Bonferroni’s test to compensate for increased type I error. Unpaired t
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test was utilized for analysis of Western Blots or other data sets that included simple
comparisons between two groups. All probabilities were two-tailed. Statistical power
was > 0.8 to determine sample size. Statistical significance was defined as a
probability of type I error occurring at < 5% (P<0.05). The minimum number of
experimental replications was 3. Graphics and analyses were performed on PRISM
5.0.
3.5. Results
3.5.1. Silica and ENM induce LMP in macrophages
Silica has been shown to cause LMP in vitro [16], and LMP has been
proposed, but not directly measured with the other ENM used in these studies [111,
5]. While fluorescent probes such as Lysotracker™, acridine orange, and others may
provide data suggestive of LMP, they fail to provide quantifiable direct measures of
LMP, and can be difficult to interpret. Therefore, we adapted recently reported
methods to quantify LMP in macrophages following particle exposure [60]. These
assays rely on selective digitonin extraction of the cytosol in order to measure
lysosomal cathepsin and hydrolase activity following LMP. Bone Marrow derived
Macrophages (BMdM) have successfully been used to model NLRP3 inflammasome
activity with particle exposure, and resemble AM responses [124]. Therefore, we
utilized BMdM to help determine mechanisms involved in LMP. BMdM were exposed
to increasing doses of silica, MWCNT, TNB, and TNS in vitro and LMP quantified at 4
hr. We also quantified LMP over an 18 hr time-course. All particles were able to
induce LMP with increasing dose (Figure 1A), however, the kinetics of LMP-induction
for each particle differed. LMP following silica exposure peaked at 4 hours, while LMP
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increased over time with ENM exposures (Figure 1B). These findings reveal
important differences between the kinetics of silica and ENM-induced LMP within the
first 18 hr of exposure in vitro. However, exposure to all particles eventually resulted
in significant LMP by 18 hr.

3.5.2. Phagolysosome acidification is necessary for particle induced LMP
Mechanisms by which bioactive particles including silica, MWCNT, and TNB
cause LMP have not been determined. Phagolysosome acidification has been
reported to play a role in pharmacologically-induced LMP with Leu-Leu-O-Me, and
this has been predicted to be the case with silica exposure [16]. The role of
phagolysosomal acidification in LMP has not been determined for MWCNT, TNB, or
TNS used in these studies. Therefore, we exposed BMdM to silica, MWCNT, TNB,
and TNS with or without the vATPase inhibitor Bafilomycin A1. We measured LMP
after 4 hr and resultant downstream NLRP3 inflammasome activity (extracellular IL1β and IL-18 levels) after 24 hr. LPS was used to prime the NLRP3 inflammasome,
and had no significant effect on LMP (data not shown). Bafilomycin A1 inhibited LMP,
as indicated by decreased cytosolic Cathepsin L activity, with all particle exposures
(Figure 2A). Leaked NAG can be used as a second indicator of LMP, and has activity
independent of cathepsins and a low pH [60]. NAG activity in the cytosolic fraction
was significantly decreased with Bafilomycin A1 treatment for all particles, confirming
the necessity of phagolysosome acidification in particle-induced LMP. Inhibition of
LMP by Bafilomycin A1 was not due to decreased phagocytosis (data not shown).

68

Finally, inhibition of LMP with Bafilomycin A1 correlated with decreased NLRP3
inflammasome activity, including the release of IL-1β and IL-18 (Figure 2D, 2E).

3.5.3. Cathepsin B is not necessary for particle-induced LMP
While most studies agree that cathepsin B is important in activating the NLRP3
inflammasome after LMP, there are reports suggesting a direct role for cathepsin B in
facilitating LMP with cholesterol crystals, adjuvants and sphingosine [54, 55, 13, 115].
This relationship has not been determined for silica and ENM exposure. Therefore, to
determine if cathepsin B was directly involved in LMP, we exposed BMdM to
bioactive particles with or without CA-074-Me treatment and assessed LMP after 4 hr.
CA-074-Me has been shown to have increased specificity towards Cathepsin B at the
dose used in these studies [16]. CA-074-Me treatment greatly decreased cathepsin L
activity in the cytosolic fraction of particle-exposed macrophages (Figure 2A). CA074-Me did not directly inhibit cathepsin L (Figure 2B). CA-074-Me treatment partially
reduced cytosolic NAG activity with silica exposure (Figure 2C), but did not reduce
cytosolic NAG activity with ENM exposures (Figure 2D). Together, these findings
support the notion that the nanoparticles used in these studies cause LMP
independent of cathepsin B, however, cathepsin B may have a marginal or indirect
role with silica exposure. Furthermore, these data show that inhibition of active
cathepsin B results in inhibition of active cathepsin L, suggesting a protease cascade
following particle exposure.
Finally, we measured IL-1β and IL-18 production with particle exposure with or
without CA-074-Me treatment at 24 hr to confirm that active cathepsin B plays an
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integral role in NLRP3 inflammasome activation. Extracellular IL-1β and IL-18 levels
were significantly reduced with CA-074-Me treatment for all particles used (Figure 2E,
2F). These data provide further support to the importance of cathepsin B after LMP in
activating the NLRP3 inflammasome in vitro.

3.5.4. Silica exposure results in LMP in vivo
We have demonstrated that the bioactive particles used in these studies cause
LMP, resulting in translocation of cathepsins into the cytosol, and activation of the
NLRP3 inflammasome in vitro. Direct evidence of LMP in vivo is sparse, let alone in
models of bioactive particle exposure. Since silica was the most potent inducer of
LMP in vitro, we utilized silica as a representative particle to determine impacts of
particle exposure on cathepsin B expression, lysosomes, and LMP in vivo. Using
silica for these studies also had the added benefit of not interfering with fluorescent
signal in laser scanning cytometry assays, which may occur with MWCNT and TNB.
We exposed C57Bl/6 mice to silica and isolated AM after 7 d, then measured
intracellular cathepsin B activity using the Magic RedTM assay, which relies on active
cathepsin B targeting of a cresyl violet conjugated substrate. This time was chosen
based on prior work showing silica, MWCNT, TNB, and TNS exhibited significant
cellular inflammation and/or pathology [111, 12, 120, 125], suggesting ongoing
NLRP3 inflammasome activity. Silica exposure significantly increased intracellular
cathepsin B activity compared to vehicle control (Figure 3A). It is possible that LMP
can result in the loss of intact lysosomes [16]. AM isolated 7 d following exposure to
silica had a lower mean fluorescence intensity (MFI) of LysotrackerTM Red staining
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compared to PBS control when assessed by laser scanning cytometry (Figure 3B).
Evaluation of histograms (MFI versus cells counted) revealed that silica exposure
caused the formation of two distinct cell populations based on MFI (Figure 3C),
suggesting that lysosomal loss could be occurring in a subset of macrophages
isolated from the lungs during persistent particle-induced inflammation.
To more directly quantify LMP at 7 d following silica exposure, we extracted
the cytosolic fraction from AM and measured leaked lysosomal enzyme activity.
Cathepsin L activity was significantly increased in the cytosol of AM from silicaexposed mice compared to PBS-treated mice, confirming LMP in vivo (Figure 3D).
NAG activity was significantly increased as well (Figure 3E). Together, these data, in
conjunction with increased cathepsin B and loss of lysosomal staining, demonstrate
LMP in vivo following particle exposure.
We previously demonstrated that CA-074-Me did not fully inhibit silica-induced
LMP in vitro, suggesting LMP can occur independent of cathepsin B activation
(Figure 2B, C). To confirm the role of cathepsin B in LMP in vivo, we treated AM from
silica-exposed mice ex vivo with CA-074-Me . CA-074-Me treatment did not
significantly reduce LMP, as indicated by no decrease in cytosolic NAG activity
(Figure 3E). However, we observed that CA-074-Me treatment did cause a
significant decrease in active cathepsin L (Figure 3E), again supporting the notion
that cathepsin B regulates the activation of other lysosomal cathepsins.

3.5.5. NLRP3 Inflammasome activity persists in vivo following particle exposure
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Mechanisms by which NLRP3 inflammasome activity persists following particle
exposure are not fully understood. We show with silica exposure that LMP is ongoing
at 7 d (Figure 3). We hypothesized LMP would be responsible for persistent NLRP3
inflammasome activity at this time-point. In order to test this, we needed to confirm
that NLRP3 inflammasome activity, including the secretion of active IL-1β and IL-18,
was persistent in vivo. For these reasons, we exposed C57BL/6 and caspase-1 null
mice to crystalline silica and assessed pulmonary inflammation at 7 d. C57BL/6 mice
had significantly elevated IL-1β and IL-18 levels in the lung lavage fluid (Figure 4A,
4B). Levels of IL-1β and IL-18 were significantly less in caspase-1 null mice
compared to wild type C57Bl/6. Total cell counts were similar between silica-exposed
mice and ENM-exposed mice at 7 d (Figure 4C), showing consistency with cellular
inflammation between various particle exposures. Total protein levels and
extracellular LDH activity were increased as well in C57BL/6 mice (Figure 4D, 4E),
supporting ongoing inflammation at 7 d.
AM have a critical role in inflammation and the development of disease with
particle exposure [12]. We hypothesized that increased NLRP3 inflammasome
associated cytokine production in vivo was a consequence of persistent NLRP3
inflammasome activity in AM. In order to determine if the NLRP3 inflammasome was
persistent in AM in vivo, we isolated AM from silica-exposed mice at 7 d and
assessed both mRNA and protein levels of NLRP3, ASC, caspase-1, and pro-IL-1β.
As predicted, mRNA levels for NLRP3 (Nlrp3), ASC (Pycard), and pro-IL-1β (Il-1β)
were significantly increased. Pro-caspase-1 (Casp1) trended upwards but was not
significant (Table 1). Protein levels followed a similar pattern, including significantly
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increased NLRP3, ASC, and pro-caspase-1 (Figures 4F, 4G). Together, these data
support that silica exposure causes NLRP3 inflammasome persistence at 7 d in AM
in vivo, correlating with ongoing LMP.

3.5.6. HMGB1 and cathepsin secretion is dependent upon caspase-1
The alarmin HMGB1 is an endogenous primer of NLRP3 inflammasome
activity through NF-κB, and can be actively secreted from macrophages or passively
released from dying cells [122, 11] [85]. Lysosomal cathepsins may also be secreted
through similar mechanisms and can participate in extracellular matrix remodeling
[63], [126]. An inflammasome dependent and independent secretion pathways for
HMGB1 have been reported with infection [85]. We have previously reported that
HMGB1 secretion is dependent upon caspase-1 with MWCNT exposure [122].
Whether caspase-1 is necessary for HMGB1 secretion following silica exposure had
not been assessed in vivo. Therefore, we exposed C57BL/6 and caspase-1 null mice
to silica and measured the levels of HMGB1 in the lavage fluid after 7 d. Caspase-1
null mice had significantly less HMGB1 in the lavage fluid compared to C57BL/6
controls (Figure 5A). We also observed significantly less cathepsin activity in silicaexposed caspase-1 null mice lavage fluid compared to silica-exposed C57Bl/6 control
(Figure 5B). Together, these data support a novel role for caspase-1 in facilitating
both the secretion of HMGB1 and cathepsins with silica exposure.

3.5.7. Persistent NLRP3 inflammasome activity is dependent upon Cathepsin B
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Our data support the notion that NLRP3 inflammasome is persistent and active
7 d following silica and ENM exposure in vivo (Figure 4), and this correlates with
ongoing LMP (Figure 3). We hypothesized that LMP and the release of cathepsin B
would be driving forces of persistent NLRP3 inflammasome activity in vivo in AM.
Consequently, we predicted inhibition of active cathepsin B with CA-074-Me in AM
isolated from particle-exposed mice would decrease NLRP3 inflammasome
cytokines. Therefore, we isolated AM from C57BL/6 mice 7 d after silica, MWCNT,
TNB, and TNS exposure and cultured them ex vivo with or without LPS or CA-074Me to inhibit cathepsin B. Stimulation of cells with low levels of LPS is often used for
priming of the NLRP3 inflammasome. After 24 hr we measured IL-1β and IL-18 in
cell supernatants (IL-18 data shown only for silica exposure). Isolated AM from silica,
MWCNT, and TNB-exposed mice secreted significantly greater amounts of IL-1β than
AM from PBS and/or TNS-exposed mice (Figure 6A, 6B). CA-074-Me treatment
significantly reduced IL-1β production ex vivo with all bioactive particle treatments
(Figure 6A, 6B). CA-074-Me also inhibited ex vivo production of IL-18 from
macrophages from silica-exposed mice (Figure 6C). To confirm this response
occurred at a more chronic time point, we utilized a model of chronic lung disease
previously established with silica [12]. AM isolated 56 d following silica exposure had
significantly more IL-1β and IL-18 secretion that could be mitigated with CA-074-Me
treatment (Figure 6D, 6E). Together, these data support persistent NLRP3
inflammasome activity in AM is dependent upon active cathepsin B, which is present
in the cytosol after LMP.
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HMGB1 has been reported to be dependent upon a cathepsin B associated
unconventional secretion pathway with starvation and nigericin co-treatment [11].
However this relationship has not been investigated in a relevant model of particle
exposure. Since we observed a dependence of HMGB1 secretion on caspase-1, we
predicted that HMGB1 secretion from macrophages could also be mitigated by
inhibiting mediators upstream of NLRP3 inflammasome activation (i.e. cathepsin B).
We again utilized silica as a representative particle to assess this relationship.
Macrophages isolated from silica-exposed mice at 7 d secreted high levels of
HMGB1 that could be decreased with CA-074-Me treatment (Figure 6F). These data
are the first showing HMGB1 dependence on active cathepsin B in a particleexposure model, and further support the notion that an active NLRP3 inflammasome
regulates the secretion of HMGB1 and cathepsins.

3.6. Discussion
Compromised lysosome integrity is an emerging paradigm with ENM
exposure, and this includes the potential for ENM to cause LMP [62]. Lysosome
dysfunction has been implicated in a number of chronic inflammatory diseases [61].
Evaluation of LMP with particle exposure primarily has been done using acidotropic
dyes or immunofluorescent staining to assess colocalization of lysosomal enzymes
[62], which can be difficult to interpret. Many nanomaterials, such as MWCNT and
TNB, could also interfere with these fluorescent assays, especially at higher doses,
further complicating assessment of LMP. Additionally, inhibitors that target lysosome
acidification, such as Bafilomycin A1, can also affect fluorescence acidotropic dyes,
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preventing mechanistic studies. In this study, we utilized methods adapted from Aits
et al., which rely on the saponic qualities of digitionin for selective extraction of the
cellular cytosolic fraction [60], allowing for assay of leaked lysosomal enzyme activity.
We show that both silica and ENM used in these studies caused a dose-dependent
increase in LMP (Figure 1A). We also observed some differences in LMP over time
between silica and ENM (Figure 1B), which could be due to multiple factors including
mechanisms of uptake. Silica phagocytosis is mediated by MARCO [127], however,
many of the uptake mechanisms of the ENM used in these studies have not been
determined, but may include caveolin-1 or clatherin-mediated endocytosis [128].
Regardless of uptake mechanism, all particles assessed in these studies caused
LMP within 18 hr, consistent with the hypothesis that lysosome dysfunction is the
critical pathway following phagocytosis leading to NLRP3 inflammasome activation.
Mechanisms by which silica and nanomaterials cause LMP have not been
determined. We demonstrated that phagosome acidification is essential for LMP and
downstream NLRP3 inflammasome activity with silica, MWCNT, TNB, and TNS
exposure (Figure 2). Phagolysosome acidification has been reported to be necessary
for LMP following Leu-Leu-O-Me exposure [16]. However, inhibition of acidification by
Bafilomycin A1 may also inhibit activation of cathepsin C, which is important in
processing Leu-Leu-O-Me to its active form that induces LMP [116, 16, 115].
Phagolysosome acidification has also been proposed with silica due to its ability to
decrease NLRP3 inflammasome associated cytokine production, however direct
inhibition of LMP with Bafilomycin A1 was not assessed in these reports [16]. While
our results show a role for acidification in particle-induced LMP, they come short of
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addressing mechanisms by which particles cause LMP. Lysosome acidification and
activation of proteases has been reported to facilitate removal of the protein corona
on phagocytosed particles, and thereby may allow for direct particle-membrane
interactions [113]. Therefore, after the protein corona is removed, this would support
the notion that specific physiochemical characteristics of the particle would define its
LMP-inducing potential. Alternatively, some studies have directly implicated cathepsin
B in LMP [116, 115, 54, 55]. We show that LMP occurs independent of cathepsin B
with ENM exposure, as NAG levels in the cytosolic fraction were not reduced with
CA-074-Me treatment (Figure 2, 3). Leaked NAG levels were partially reduced with
silica exposure and CA-074-Me treatment in BMdM, suggesting a minor or indirect
role for cathepsin B in this model. Particle-induced membrane damage via ROS has
also been proposed as a mechanism of LMP [47]. Nonetheless, mechanistic
understandings of the contribution of these pathways (ROS and/or direct particlemembrane interactions) to initiating LMP have not been described.
In vivo studies supporting LMP are lacking [61]. There are multiple reports of
LMP in vitro with a broad range of agonists and only one report showing an in vivo
role for LMP in mammary tissue reduction [129]. Consequently, little is known on the
contribution of LMP to NLRP3 associated inflammation beyond what is observed in
vitro. These studies are the first to show direct evidence of particle-induced LMP in
AM 7 d following in vivo silica exposure (Figure 3D, 3E). Ongoing LMP, including the
leak of active cathepsins into the cytosol, could potentially drive persistent NLRP3
inflammasome activity. Our observation of LMP and increased active cathepsin B in
AM (Figure 3A, 3D, 3E) correlated with increased NLRP3 inflammasome activity at 7
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d in vivo (Figure 4A, 4B). Persistent NLRP3 inflammasome activity in AM was
mitigated ex vivo with CA-074-Me treatment (Figure 6). Cytosolic cathepsin activity is
known to cause NLRP3 inflammasome activation in vitro, and therefore the
therapeutic effects of CA-074-Me in AM ex vivo is likely due to inhibition of cytosolic
cathepsin B resulting from ongoing LMP. This would support the hypothesis that
cytosolic cathepsin B is responsible for persistence of NLRP3 inflammasome activity.
Further novel findings of this work are that cathepsin B inhibition with CA-074Me regulates the activity of cathepsin L (Figure 2A, 3D). Others have reported a
specific role for cathepsin C in causing LMP and regulating cathepsin B [116].
However, these studies were not done within a relevant particle exposure model, and
are not conclusive on the interactions between cathepsin B and cathepsin C. Our
findings and these reports may indicate the possibility of a protease cascade within
the lysosome following particle exposure. We can conclude that inhibition of
cathepsin B suppresses NLRP3 inflammasome activity, and since inhibiting cathepsin
B also inhibits other cathepsins, there may also be other intermediate cathepsins
regulating NLRP3 inflammasome activity not accounted for. Further studies are
required to determine the involvement of other cathepins in NLRP3 inflammasome
activation.
It is important to note that we observed significant differences in the magnitude
of NLRP3 inflammasome activity in AM at 7 d between silica and MWCNT exposures
(Figure 5A, 5B). This is likely due to a number of factors involved in IL-1β production
including differences in particle dose, surface area, physiochemical properties, and
clearance. Because of these differences, it is difficult to directly compare bioactivity of
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ENM to silica without further dosimetry evaluation, although the critical pathway
(lysosome membrane permeabilization) is the same.
HMGB1 is a Danger associated Molecular Pattern/alarmin that is released by
dead or dying cells, and can be actively secreted by macrophages [85, 17]. Once
outside of the cell, HMGB1 has both pro-inflammatory and chemotactic activity [130,
22]. Both HMGB1 and IL-18 have been implicated in autoimmune diseases such as
SLE, which has increased prevalence in individuals with silicosis [24, 3, 25]. We have
previously reported that HMGB1 participates in sterile priming of the NLRP3
inflammasome in vitro and in vivo with MWCNT exposure [122]. While we did not
investigate the contribution of HMGB1 in silica or TNB-associated NLRP3
inflammasome activity, we suspect a commonality with MWCNT exposure. HMGB1
release has been reported to be dependent upon NLRP3 inflammasome activation
with endotoxemia, ATP, and nigericin exposure [18]. In these studies, we further
show that HMGB1 secretion in vivo is dependent upon caspase-1 and cathepsin B
with silica exposure (Figure 5A, 6F). Extracellular cathepsin activity was also
dependent upon Caspase-1, suggesting the NLRP3 inflammasome is regulating
unconventional secretion of both HMGB1 and proteases. An autophagy-based
unconventional secretion pathway has been reported for the secretion of HMGB1 and
NLRP3 inflammasome associated cytokines with nigericin and starvation [11].
Autophagic activity has been reported to be altered with silica exposure [131],
however, further studies are needed to determine if autophagy contributes to an
NLRP3 inflammasome dependent secretion pathway following silica and ENM
exposure.
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In summary, this study demonstrates several novel findings that further our
understanding of mechanisms driving persistent NLRP3 inflammasome activity and
particle-induced LMP. First, we highlight the necessity of phagolysosome
acidification as a common prerequisite to particle-induced LMP, and show cathepsin
B does not play a direct role in causing LMP. Secondly, we provide evidence of LMP
in AM in vivo, and resultant cytosolic cathepsin B activity drives persistent NLRP3
inflammasome activity in AM ex vivo. Finally, we provide evidence supporting a
cathepsin B and NLRP3 inflammasome associated mechanism for the secretion of
HMGB1. These findings are highlighted in Figure 7. These studies support that
targeting cathepsin B and/or LMP through lysosomal stabilization may be a
therapeutic strategy for reducing particle-induced chronic inflammatory disease.
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Table 3: NLRP3 Inflammasome components are increased with silica exposure
Gene

Fold Change

Std. Error

P Value

Casp1

1.774

0.719 – 4.804

0.356

Il-1β

6.509

1.227 – 24.183

0.033*

Nlrp3

2.773

1.770 – 4.774

0.000***

Pycard

2.390

1.159 – 3.752

0.004***

Lung lavage cells were collected at 7 d after silica exposure for analysis of mRNA
expression levels. Expression is presented as fold change caused by particle
treatment over PBS control after normalization to reference genes. Values are shown
as mean ± SD (N=4). * P < 0.05, *** P < 0.001 indicates significant increase in
transcription compared to PBS control.
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3.8. Figures

FIGURE 1
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Figure 3.1. Silica and ENM exposure cause LMP in macrophages. (A) BMdM were
exposed to increasing doses of silica, MWCNT, TNB, and TNS and LMP (leaked
cathepsin L) measured in the cytosolic fraction at 4 hr. (B) LMP over time with particle
dose of 50 µg/mL. Data are presented as mean ± SEM (N=3). *P < 0.05, **P < 0.01,
***P < 0.001 when compared to baseline.
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FIGURE 2
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Figure 3.2. Particle-induced LMP in macrophages is dependent on phagolysosome
acidification in vitro. BMdM were exposed to silica, MWCNT, TNB, or TNS (all 50
µg/mL) with or without Bafilomycin A1 (100 nM) or CA-074-Me (10 µM) and LMP
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assessed after 4 hr. (A) Cathepsin L activity in the cytosolic fraction. (B) CA-074-Me
does not inhibit Cathepsin L activity when CA-074-Me (10 µM) was added in situ to
cellular extracts and incubated for 30 minutes. (C) NAG activity in the cytosolic
fraction following exposure (crystalline silica only). (D) NAG activity in the cytosolic
fraction following MWCNT, TNB, and TNS exposure. (D) IL-1β levels in BMdM cell
supernatants 24 hr after particle exposure, LPS stimulation (20 ng/mL), and treatment
with Bafilomycin A1 (100 nM) or CA-074-Me (10 µM). (E) IL-18 levels in the cell
supernatants after 24 hr. Data show mean ± SEM (N=3). *P < 0.05, **P < 0.01, ***P <
0.001 indicate significance compared to particle exposures without CA-074-Me or
Bafilomycin A1 treatment.
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FIGURE 3
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Figure 3.3. LMP is increased in AM 7 d following silica exposure in vivo. AM were
isolated 7 d following silica (40 mg/kg) or PBS exposure and assessed for active
cathepsin B, lysosomal loss with Lysotracker RedTM, and leaked lysosomal enzymes
cathepsin L and NAG using digitonin extraction. (A) Representative LSC images (40X
scan) and figure showing Mean Fluorescent Intensity (MFI per total cells counted) of
cathepsin B for combined experiments (N=4, 2 mice pooled for each N). (B)
Representative LSC images (60X scan) of Lysotracker RedTM staining with figure
showing MFI of Lysotracker RedTM for combined experiments. (C) Histogram overlays
of Lysotracker RedTM MFI integrals from combined experiments (N=4, 2 mice pooled
for each N). (D) Cathepsin L activity in cytosolic fraction. (E) NAG activity in cytosolic
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fraction. CA-074-Me (10 µM) was added to AM cultures for 2 hours ex vivo. Data are
shown as mean ± SEM (N=4). *P < 0.05, **P < 0.01, ***P < 0.001 indicate
significance when compared to control.
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FIGURE 4
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Figure 4.4. Bioactive particle exposure causes persistent NLRP3 inflammasome
activity in vivo. (A) IL-1β levels in the whole lavage fluid of C57Bl/6 and caspase-1
null mice 7 d following instillation of PBS or silica (40 mg/kg). (B) IL-18 levels in lung
lavage fluid at 7 d. (C) Cell counts 7 d after silica and ENM (2 mg/kg) instillation. (D)
LDH and (E) total protein levels in the lavage fluid of silica or PBS exposed C57Bl/6
mice at 7 d. (F) Intracellular NLRP3 and ASC protein levels in isolated AM from
C57Bl/6 mice 7 d following silica exposure. (G) Intracellular caspase-1, pro-IL-1β, and
cleaved IL-1β protein levels. Western Blots shown are representative of 3 separate
experiments with lung lavage cells from 3 mice pooled for each lysate. All samples
were derived at the same time and processed in parallel for western blot analysis.
Data are presented as mean ± SEM (N= 3 to 4). *P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 5
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Figure 3.5. Secretion of HMGB1 and cathepsins is dependent upon caspase-1 in
vivo. (A) HMGB1 levels in the lavage fluid of C57Bl/6 and caspase-1 null mice 7 d
following exposure to silica (40 mg/kg). (B) Cathepsin (CTS) activity in the lavage
fluid at 7 d. Data are presented as mean ± SEM (N=4). *P < 0.05, ***P < 0.001.
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FIGURE 6
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Figure 3.6. Cathepsin B activity drives persistent NLRP3 inflammasome activity and
HMGB1 release from AM ex vivo. AM were isolated from C57BL/6 mice 7 d following
silica (40 mg/kg), MWCNT, TNB, and/or TNS (2 mg/kg) exposure and cultured ex
vivo with/without LPS (20 ng/mL) stimulation and CA-074-Me (10 µM). Cytokine
levels were measured in cell supernatants after 24 hr of ex vivo culture. (A) IL-1β
levels in supernatants of AM from silica or PBS exposed mice (7 d). (B) IL-1β levels
in supernatants of AM from MWCNT, TNB, and TNS or vehicle exposed mice (7 d).
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(C) IL-18 levels in supernatants of AM from silica or PBS exposed mice (7 d). (D) IL1β levels in supernatants of AM from silica or PBS exposed mice (56 d). (E) IL-18
levels in supernatants of AM from silica or PBS exposed mice (56 d) (F) HMGB1
levels in supernatants of AM from silica or PBS exposed mice (7 d). Data are shown
as mean ± SEM (N=4). *P < 0.05. **P < 0.01. ***P < 0.001.
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FIGURE 7

Figure 3.7. Model of particle-induced LMP and resultant NLRP3 inflammasome
activity. Phagosomes containing the particle become more acidic as they move down
the endocytic pathway and fuse with lysosomes. Phagolysosome acidification is
necessary for particle-induced LMP. LMP results in the release of cathepsins into the
cytosol, which in turn activate the NLRP3 inflammasome. NLRP3 inflammasome
activity regulates the secretion of pyrogenic cytokines IL-1β and IL-18, as well as the
alarmin HMGB1.
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4.2. Abstract
Autophagy is an important metabolic mechanism that can promote cellular survival
following injury. The specific contribution of autophagy to silica-induced inflammation
and disease is not known. The objective of these studies was to determine the effects
of silica exposure on the autophagic pathway in macrophages, as well as the general
contribution of autophagy in macrophages to inflammation and disease. Silica
exposure enhanced autophagic activity in vitro in Bone Marrow derived Macrophages
and in vivo in Alveolar Macrophages isolated from silica-exposed mice. Impairment of
autophagy in myeloid cells in vivo using Atg5fl/flLysM-Cre+ mice resulted in enhanced
cytotoxicity and inflammation after silica exposure compared to littermate controls,
including elevated IL-18 and the alarmin HMGB1 in the whole lavage fluid. Autophagy
deficiency caused some spontaneous inflammation and disease. Greater silicainduced acute inflammation in Atg5fl/flLysM-Cre+ mice correlated with increased
fibrosis and chronic lung disease. These studies demonstrate a critical role for
autophagy in suppressing silica-induced cytotoxicity and inflammation in disease
development. Furthermore, these data highlights the importance of basal autophagy
in macrophages and other myeloid cells in maintaining lung homeostasis.

Keywords: Autophagy, NLRP3 Inflammasome, HMGB1, IL-1β, IL-18, Silica
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4.3. Background
Autophagy is critical in maintaining cell homeostasis and is generally
considered a pro-survival mechanism. While there are multiple types of autophagy,
these studies focus primarily on macroautophagy, which has a fundamental
responsibility of sequestering and degrading large macromolecular protein structures
and damaged organelles [67]. In the autophagic process, cytosolic microtubuleassociated protein 1A/1B-light chain 3 (LC3-I) is cleaved to the LC3-II isoform and
incorporated into the forming autophagosome membrane. Atg5 is a critical protein
required for autophagosome elongation and LC3 lipidation [132]. Macromolecular
structures are targeted towards the autophagic pathway through hyper-ubiquitination
and the autophagy specific chaperone SQSTM1 (p62) [69]. Targeted material and
p62 is sequestered within autophagosomes, which fuse with lysosomes in order to
degrade and recycle the target and carrier proteins. Autophagy is reported to be a
primary mechanism for degradation of the AIM2 and NLRP3 inflammasomes [72].
Therefore, regulating autophagy could possibly have profound implications in
macrophage responses to pro-inflammatory and cytotoxic environmental particles.
Recent reports highlight that silica exposure and the development of
pneumoconiosis continues to be a significant health concern [133]. There are few
studies investigating the contribution of autophagy to lung disease, let alone those
caused by exposure to hazardous particulates such as silica. Failure of autophagy to
degrade inflammasomes and clear bulk damaged organelles and protein aggregates
are thought to contribute to the development of chronic lung disease. However, the
state of autophagy appears to vary with different types of chronic lung diseases [134].
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Autophagy is reported to be greatly enhanced in Chronic Obstructive Pulmonary
Disease in epithelial cells, while autophagic flux is impaired in isolated alveolar
macrophages following cigarette smoke exposure [135, 136]. On the other hand,
autophagy is reportedly decreased in bleomycin-induced fibrosis in vivo, and in
human Idiopathic Pulmonary Fibrosis and Cystic Fibrosis [137, 138]. The role and
state of autophagy in silicosis has not been determined, but may differ from these
other lung diseases due to alternative mechanisms of action.
Chronic NLRP3 inflammasome activity and cell death is reported to drive the
development of pathology following silica exposure [107]. Previous studies have
shown that innate immune function is sufficient for the development of fibrosis in a
mouse model of silicosis, suggesting a critical role for macrophages in the chronic
inflammatory response [12]. A primary mechanism by which silica induces NLRP3
inflammasome activation and cell death in macrophages is through permeablization
of phagolysosomes [16]. The autophagic pathway also shares lysosomes as a
common endpoint for degradation of sequestered material. However, the
consequences of silica exposure on autophagic flux through the lysosome are not
known.
In the current study, we investigated the contribution of autophagy in lung
macrophages, in response to silica-induced inflammation and disease. For this study
we used Atg5fl/flLysM-Cre+ mice, which lack essential machinery necessary for the
formation of autophagosomes in cells that express high levels of lysozyme, which
include macrophages and other myeloid cell populations [139]. Therefore, we
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expected that there would be greater inflammation and disease following silica
exposure in mice in which autophagic activity has been impaired.

4.4. Material and Methods
4.4.1. Particle preparation
Acid washed crystalline silica (Min-U-Sil-5; mean particle diameter 1.5-2 µm) was
obtained from Pennsylvania Glass Sand Corp (Pittsburgh, PA, USA). Silica was
determined to have insignificant levels of endotoxin (LPS) by the Limulus
amoebocyte lysate assay (Cambrex, Walkersvill, MD, USA) as previously described
[12, 140]. Prior to instillation into mice or addition to cell cultures, silica particles were
suspended in PBS and sonicated for >1 min (550 watts @ 20 kHz) by a cup-horn
sonicator in a circulating water bath (Misonix, Inc. Farmingdale, NY, USA).

4.4.2. Mice
Transgenic GFP-LC3 mice, which express green fluorescent protein (GFP) fused to
microtubule-associated protein 1A/1B-light chain 3 (LC3), were generously donated
by Dr. Aruni Bhatnagar (University of Louisville, KY, USA) and have been previously
described [141]. Homozygous Atg5fl/fl mice were obtained from the RIKEN BRC
through the National Bio-Resource Project of the MEXT, Japan, courtesy of Dr.
Noboru Mizushima [142]. LysM-Cre+ mice were obtained from Jackson Laboratories.
Crossing of homozygous Atg5fl/fl mice with LysM-Cre+ to generate the Atg5fl/flLysMCre+ mice was tracked and confirmed by PCR as previously described [142, 143].
Autophagy knockout in was confirmed by Western Blot in Bone Marrow derived
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Macrophages (BMdM) from Atg5fl/flLysM-Cre+ mice. Western Blot analysis included
confirming deficiency in Atg5 (data not shown) and blocked lipidation of LC3-I to LC3II. Both male and female C57Bl/6 (Jackson Laboratories, Bar Harbor, ME, USA),
GFP-LC3 and Atg5fl/flLysM-Cre+ mice were used in equal numbers for all studies.
Mice were housed in micro-isolators in a specific pathogen-free facility under a 12:12hr light-dark cycle. Food, bedding, and cages were sterilized by autoclaving. Mice
were used between 8-16 wk of age. The University of Montana Institutional Animal
Care and Use Committee (Missoula, MT, USA) approved all procedures performed
on the animals.

4.4.3. Bone Marrow derived Macrophages
Bone Marrow derived Macrophages (BMdM) were generated as described previously
[140]. Briefly, BMdM were obtained by flushing the femur and tibia following sacrifice
of C57Bl/6, GFP-LC3, and Atg5fl/flLysM-Cre+ and/or Littermate control mice. Bone
marrow isolate was then cultured in T75 culture flasks with 20 mL of RPMI (10 %
FCS) overnight for stromal cell elimination. Non-adherent cells were aspirated and
seeded in a new T75 flask (15 x 106 cells/flask) in 20 mL and 40 µL Macrophage
Colony Stimulating Factor (M-CSF, 10 ng/mL stock, R&D Systems, Minneapolis, MN,
USA) added to each flask. Cultures were maintained for 7-10 days with re-feeding
every 3-4 days.
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4.4.4. In vitro studies
BMdM from Atg5fl/flLysM-Cre+ mice and littermate controls were plated at 1x105
cells/well in a 96 well plate and exposed to silica (100 µg/mL) and LPS (20 ng/mL) to
prime the NLRP3 inflammasome. After 24 hr, cell supernatants were collected and
assessed for markers of inflammation and cell death. For analysis of GFP-LC3 in
BMdM, cells were plated in a 96 well culture dish with a glass bottom coverslip
(MatTeck Corp. Ashland, MA, USA) at 1x105 cells/well. Macrophages were then
exposed to silica (100 µg/mL) with or without Bafilomycin A1 (100 nM, EnzoLife
Sciences, Farmingdale, NY, USA) to inhibit autophagic flux. BMdM were also treated
with 3-methyladenine (3-MA, 5 µM, Sigma-Aldrich, Saint Louis, MO, USA) to inhibit
autophagosome formation. After 24 hr, GFP-LC3 was assessed by laser scanning
cytometry.

4.4.5. In vivo studies
Atg5fl/flLysM-Cre+ mice and littermate control mice were instilled with silica at 40
mg/kg (~1 mg/mouse), which has previously been shown to induce sufficient acute
inflammation in vivo [12, 140]. Mice were sacrificed 24 hr after silica exposure for
analysis of the whole lung lavage fluid and cell differentials. Mice were lavaged by
instilling, aspirating, and re-instilling 1 mL of cold PBS (3X) to concentrate lavage
cytokines. An additional two more rounds of 1 mL PBS instillation/aspiration were
performed to maximize cell retrieval. Isolated whole lung lavage cells were counted
using a Coulter Z2 particle counter (Beckman Coulter, Brea, CA, USA). Cells were
then stained for differential analysis using Wright’s Geimsa and a Hematek 2000
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autostainer (Miles-Bayer-Siemens Diagnostics, Deerfield, IL, USA). Macrophage area
on differential slides was assessed via ImageJ Analysis Software. Using similar
methods, whole lung lavage cells were isolated from C57Bl/6 or GFP-LC3 mice 7 d
following silica exposure for analysis of autophagy by confocal microscopy or
Western Blot. For chronic studies, Atg5fl/flLysM-Cre+ mice and littermate control mice
were instilled with silica (40 mg/kg) once a week for 4 consecutive weeks as
described previously [12, 140]. Twenty eight days after the final instillation (day 56),
the mice were sacrificed and their lungs inflated with 4% paraformaldehyde for
histology. Fixed lungs were embedded in paraffin and sectioned (7 µm), and mounted
on Superfrost+ VWR slides (VWR, Radnor, PA, USA). Sections were stained with
Gomori’s Trichrome (EMD Chemicals, Gibbstown, NJ, USA) or hematoxylin-eosin
(RAS Harris Hematoxylin and Shandon Alcohol Eosin) using a Leica ST5010
Autostainer (Buffalo Grove, IL, USA).

4.4.6. Laser Scanning Cytometry
GFP-LC3 was assessed using a CompuCyte iCys Laser Scanning Cytometer (LSC;
Westwood, MA, USA). Non-adherent BMdM were removed prior to analysis by
gentle washing of each well once with PBS. GFP-LC3 positive cells were counterstained with Molecular Probes HCS NuclearMask Blue (Life Technologies, Carlsbad,
CA, USA) according to manufacture’s instructions. GFP-LC3 was detected using a
488 nm laser as the excitation source and a PMT detector with a 530/30 nm
bandpass filter. The nuclear staining was excited with a 405 nm laser and detected
with a 440/30 nm bandpass filter/PMT set. The iCys was programmed to make 0.15
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µm x-steps (setting pixel size/resolution) on an automated stage using a 60x inverted
objective to interrogate a field size of 150 µm x 125.6 µm each step. Individual
passes of the 488 nm and 405 nm lasers were used to avoid any spectral overlap of
the “blue” and “green” fluorescent signals. A threshold of “blue” fluorescence was set
such that the software draws a contour around the nucleus of the cell. The contour is
then expanded by 25 pixels to include the cytoplasm of the cell. Each cell (as defined
by nuclear staining) is plotted on a histogram showing green Median Fluorescent
Intensity (MFI). Additionally, GFP puncta were counted per each cell using standard
integrated filters and threshold within the CompuCyte software. Regions were defined
within each well of the 96-well plate to include approximately 1500 cells to achieve
sufficient sample representation. Isolated lung lavage cells from GFP-LC3 mice were
seeded at 1 x 105 cells/well in RPMI in an 4-well glass bottom dish (Greiner Bio-One,
Monroe, NC, USA), counterstained with Molecular Probes HCS NuclearMask Blue
(Life Technologies), and examined immediately using an Olympus FV 1000 IX
inverted laser scanning confocal microscope.

4.4.7. Cytokine and Cytotoxicity Assays
BMdM cell supernatants and whole lung lavage fluid were assayed for LDH activity
(Promega, Madison, WI, USA). Cytokines IL-1β, CXCL1, and IL-1α were measured
by ELISA (R&D systems, Minneapolis, MN, USA). HMGB1 was assessed by an inhouse ELISA as previously described [122]. IL-18 was also assessed by an in-house
ELISA [6]. Extracellular cathepsin activity was assessed as previously described by
our laboratory [123]. Briefly, 2 µg Z-LR-AMC (specific to cathepsin B, cathepsin L and
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cathepsin V; R&D systems) in PBS was added to 50 µL of whole lung lavage fluid in
a total reaction volume of 150 µL. The assays were incubated at 37°C for 1 h then
fluorescence was measured using a plate reader at 380 nm excitation and 460 nm
emission.

4.4.8. Western Blot
BMdM or cells isolated from lung lavage fluid were lysed directly in RIPA buffer
containing HALTTM protease inhibitors (Life Technologies). For in vivo assessment of
autophagic markers, whole lung lavage cells from 4 mice were pooled for each N.
Lysates were run on 12-4% Bis-Tris SDS-PAGE gels. Anti-LC3, p62, ubiquitin, and
GAPDH antibodies were obtained from Cell Signaling (Danvers, MA, USA). GAPDH
was used as the loading control. Protein bands were quantified with Image J software
(NIH, Bethesda, MD, USA).

4.4.9. Microscopy and pathology scoring
Gomori’s Trichrome and H&E stained mouse lung tissue sections were imaged using
a Zeiss Axioskop attached to a Zeiss digital camera. Two expert observers scored
the lung disease using a 5-point scale (0, 1, 2, 3, and 4) with 0 being no effect and 4
being maximum lung pathology evident. The scorers were blinded to mouse
treatments. Cronbach’s-α was used to assess the reliability between the scorers.
Inter-scorer reliability was significant at 0.86.
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4.4.10. Statistical analysis
Statistical analyses involved comparison of means using a one- or two-way ANOVA
followed by a Bonferroni’s test or Holm- Šídák test to compensate for increased type I
error. Unpaired t test was utilized for analysis of Western Blots or other data sets that
included simple comparisons between two groups. Statistical power was > 0.8 to
determine sample size. Statistical significance was defined as a probability of type I
error occurring at < 5% (P<0.05). The minimum number of experimental replications
was 3. Graphics and analyses were performed on PRISM 5.0.

4.5. Results
4.5.1. Silica particle increases autophagy in macrophages
Crystalline silica is reported to cause lysosome membrane permeabilization,
which consequently leads to NLRP3 inflammasome activity and the activation of cell
death pathways [16]. Silica’s ability to compromise lysosomal integrity and cause
intracellular damage likely has broad impacts on other cell pathways, including
autophagy, however this relationship has not been investigated sufficiently.
Therefore, to assess the effects of silica exposure on autophagy, we exposed BMdM
from GFP-LC3 mice to silica and measured changes in GFP-LC3 expression and
compartmentalization after 24 hr. BMdM were used for these studies due to their
consistency in response with Alveolar Macrophages (AM) in prior studies by our
laboratory [124]. In order to test silica’s ability to increase autophagosome formation
and/or block autophagic flux, Bafilomycin A1, an inhibitor of lysosomal vATPases,
was added along with the particle [144]. 3-MA is an inhibitor of class III PI3-kinases
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and prevents autophagosome formation [71], and was added to the BMdM cultures to
further test silica’s ability to induce autophagy. A dose of 100 µg/mL of silica was
used for these studies based on prior reports by our laboratory in which this dose was
shown to maximize inflammasome activity while minimizing cell death [127]. Silica
exposure caused a marginal increase in median fluorescent intensity (MFI) of GFPLC3 per cell and a significantly increased number of GFP-LC3 puncta/cell (Figure 1A,
1B, and 1C). 3-MA effectively blocked autophagy in silica-exposed BMdM, indicating
silica exposure results in autophagic induction. As expected, Bafilomycin A1
treatment of control cells resulted in an accumulation of GFP-LC3. When Bafilomycin
A1 was added to silica-exposed cells, there was an increase in GFP-LC3 when
compared to Bafilomycin A1 only treated cells, which further supports the notion that
silica exposure is increasing autophagosome formation but not necessarily blocking
autophagic flux through the lysosome.
To further confirm that silica exposure was increasing autophagy rather than
blocking autophagic flux, we assessed LC3-I and LC3-II, the autophagy associated
ubiquitin-specific chaperone p62, and total ubiquitinated protein levels by Western
Blot [144, 145]. Both intracellular p62 and total ubiquitinated protein levels were
elevated in BMdM 24 hr following silica exposure (Figure 1D). Silica exposure
increased LC3-II, consistent with increased autophagosome formation and with the
observed increase in number of GFP-Puncta/Cell shown in Figure 1B. When silicaexposed cells were treated with Bafilomycin A1, we saw further increases in LC3-II,
p62, and total ubiquitinated protein when compared to Bafilomycin A1-treated control.
Together, these data further support the notion that silica exposure increases
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induction of autophagy in macrophages, but does not necessarily result in impaired
autophagic flux through the lysosome.

4.5.2. Silica exposure enhances autophagy in AM in vivo
To determine if silica exposure increases autophagy in AM in vivo, we instilled
C57Bl/6 mice with crystalline silica and assessed autophagy markers in isolated lung
lavage cells lysates after 7 d. Lung lavage cells at this time are primarily composed of
AM with some neutrophil influx (Figure 2A). Isolated AM from silica-exposed mice
exhibited increased LC3-I and LC3-II levels, indicating increased autophagy (Figure
2B). P62 levels were also significantly elevated (Figure 2B), as well as was total
ubiquitinated protein (Data not shown). Isolated lung lavage cells from GFP-LC3 mice
at 7 d had increased GFP-LC3 fluorescence and puncta (Figure 2C), further
supporting our findings by Western Blot. Together, these data provide consistency in
in the autophagic response to silica exposure between BMdM in vitro and AM in vivo.

4.5.3. Autophagy deficiency in macrophages enhances cell death and HMGB1
release
Autophagy has been reported to be a primary mechanism for the degradation
of assembled inflammasomes, specifically AIM2 and NLRP3 [72]. Consequently,
autophagy can potentially regulate the secretion of inflammasome-associated
cytokines. The role of autophagy in regulating NRLP3 inflammasome activity
following exposure to silica has not been previously described. Additionally,
autophagy is generally regarded as a cell survival mechanism, and may act to
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prevent silica-induced cytotoxicity. In order to test the role of autophagy in silicainduced NLRP3 inflammasome activity and cell death, we generated BMdM from
Atg5fl/flLysM-Cre+ mice, which are deficient in autophagosome formation. Though
Atg5fl/flLysM-Cre+ mice have been utilized by multiple other groups [146, 139, 11,
143], we confirmed BMdM generated from these mice exhibited impaired autophagy
to establish reproducibility of the model. This included specifically determining Atg5
depletion (data not shown) and defective lipidation of LC3-I to LC3-II (Figure 3A). We
then exposed BMdM generated from littermate control and Atg5fl/flLysM-Cre+ mice to
silica and LPS, which was added simultaneously with the particle in order to prime
the NLRP3 inflammasome and cause cytokine production over 24 hr. Silica exposure
did not significantly increase extracellular IL-1β levels in BMdM cultures from
Atg5fl/flLysM-Cre+ mice when compared to littermate controls (Figure 3B). However,
there was spontaneous (background) release of IL-1β at low levels from non silicaexposed autophagy deficient BMdM. This suggested some basal level of NLRP3
inflammasome activity in macrophages in which autophagy is impaired. Atg5fl/flLysMCre+ macrophages were more susceptible to cell death than littermate controls, as
indicated by increased LDH in cell supernatants following silica exposure (Figure 3C).
HMGB1 release has been associated with NLRP3 inflammasome activation and cell
death with bacterial infection, and exposure to carbon nanotubes [122, 20]. We
observed increased HMGB1 release from silica exposed Atg5fl/flLysM-Cre+ BMdM
compared to silica-exposed littermate controls (Figure 3D). We suspect HMGB1
release was due in part to more cell death. These data are consistent with the notion
that autophagy functions to prevent silica-induced cytotoxicity, and supports the
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proposal that autophagy deficiency results in some spontaneous NLRP3
inflammasome activity.

4.5.4. Autophagy deficiency enhances silica-induced acute inflammation in vivo
In order to determine if autophagy impairment in macrophages results in
increased acute inflammation and cytotoxicity in vivo, we exposed Atg5fl/flLysM-Cre+
mice to silica and assessed parameters of inflammation in the whole lung lavage fluid
after 24 hr. Silica exposure resulted in significant increases in total protein, HMGB1,
and IL-18 in the lavage fluid of Atg5fl/flLysM-Cre+ mice compared to silica-exposed
littermate controls (Figure 4A, 4B, 4C). IL-1β was not significantly increased in
Atg5fl/flLysM-Cre+ mouse lavage fluid compared to silica-exposed littermate controls,
but was significantly increased over PBS-exposed animals (Figure 4D). We observed
some spontaneous (background) IL-18 production in Atg5fl/flLysM-Cre+ mice (Figure
4C). Consistent with our findings in BMdM exposed to silica in vitro, LDH levels were
greater in the lavage fluid of Atg5fl/flLysM-Cre+ mice compared to littermate controls
(Figure 4E). Extracellular Cathepsin activity was also increased in autophagy
deficient mice compared to littermate controls, though not significantly (Figure 4F).
These data support the notion that depletion of autophagy in macrophages causes
some basal NRLP3 inflammasome activity. Furthermore, the observation that
inflammation and cytotoxicity (LDH) were exacerbated in Atg5fl/flLysM-Cre+ mice
demonstrates a fundamental role for autophagic suppression of silica-induced lung
injury.
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4.5.5. Autophagy deficiency in macrophages causes a basal pro-inflammatory
phenotype in vivo
In our assessment of the acute inflammatory response following silica
exposure, some findings suggested a basal phenotype when autophagy was
impaired, including spontaneous IL-18 production (Figure 4C). We also observed
increased cell numbers, mainly due to increased neutrophils in the Atg5fl/flLysM-Cre+
mice (Figure 5A) suggesting background inflammation. Neutrophil influx in PBSexposed Atgfl/flLysM-Cre+ mice correlated with elevated CXCL1 in the lavage fluid
(Figure 5B). Other investigators have reported similar observations, as well as
elevated levels of IL-1α [139, 146]. However, we did not observe increased IL-1α in
the whole lung lavage fluid of Atgfl/flLysM-Cre+ mice, and there was no significant
difference in IL-1α after silica exposure between autophagy deficient and littermate
control mice (Figure 5C). This discrepancy could be due to differences in lung lavage
fluid levels or more likely the interstitial/intracellular levels assayed with whole lung
homogenization used in the other studies [139]. During differential analysis, we
noticed that AM from Atg5fl/flLysM-Cre+ mice were much larger than those observed
in littermate controls (Figure 5D), which may indicate further differences in
macrophage activity and phenotype. These data highlight the importance of
macrophage-associated autophagy in maintaining homeostasis, and that knocking
out autophagy in macrophages results in an unusual basal phenotype that may
contribute to greater inflammation following particle exposure.

4.5.6. Autophagy deficiency in macrophages increases silica-induced lung pathology
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Next, we examined whether autophagy deficiency in macrophages and other
cells of myeloid origin results in greater chronic disease in vivo following silica
exposure. Atg5fl/flLysM-Cre+ mice and littermate controls were exposed to silica (40
mg/kg) once a week for 4 consecutive weeks, then we evaluated the mice at 56 d
following the first instillation for pathology and fibrosis [12]. We observed no
differences in weight between littermate controls and Atg5fl/flLysM-Cre+ over the
course of this study (data not shown). Autophagy deficient mice exposed to silica
exhibited more significant pathology than littermate controls exposed to silica (Figure
6A). In parallel, we observed more pathology and fibrosis in the silica exposed
Atg5fl/flLysM-Cre+ mice as determined by Trichrome staining (Figure 6B). PBS
exposed Atg5fl/fl LysM-Cre+ mice had slightly elevated pathology score compared to
littermate controls, consistent with the altered phenotype and elevated IL-18 levels at
baseline as previously discussed. These studies demonstrate that autophagy in
macrophages is important in mitigating silica-induced chronic disease.

4.6. Discussion
NLRP3 inflammasome activity in macrophages is a central driver of silica-induced
chronic inflammation and lung disease [107], [12]. An inherent role for autophagy is to
sequester and degrade inflammasomes and inflammasome cytokines such as pro-IL1β [72, 147, 71]. Therefore, autophagic stimulation is being investigated as a
potential therapeutic target for chronic inflammatory conditions. Ineffective
autophagic suppression of NLRP3 inflammasome activity may, in part, be a
mechanism contributing to chronic NLRP3 inflammasome activity with silica
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exposure. We initially hypothesized that silica-induced NLRP3 inflammasome activity
would be due, in part, to impaired autophagic flux through the lysosome. This has
been reported to be the case for rare-earth nanomaterials [73]. There is some
evidence of altered autophagic activity with silica exposure in vivo, including an
accumulation of p62 within granulomas [148], though a very high dose of silica was
used in those studies. Others reported that autophagy is impaired in isolated human
lung AM from individuals with silicosis, including increased levels of LC3, p62, and
Beclin-1 [131]. In the same study, autophagy alteration by silica was suggested to
contribute to AM sensitization to LPS stimulation, though exactly how this occurs was
not clear. Our data showing increased LC3-II, p62, and total ubiquitination in vitro and
vivo are consistent with reports in human AM (Figure 1 and 2). We were also able to
show that 3-MA effectively inhibited silica-induced autophagy (Figure 1), indicating
that silica-exposure is causing autophagic induction. Secondly, through inhibiting
lysosomal activity with Bafilomycin A1, we demonstrated further accumulation of
autophagic carrier proteins (Figure 1), which supports the hypothesis that the primary
outcome of silica exposure on the autophagic pathway is induction and not
necessarily impaired autophagic flux. Silica exposure is known to induce lysosome
membrane permeabilization (LMP), which can result NLRP3 inflammasome activation
and cytotoxicity [16]. Increased autophagy following silica exposure may be a
mechanism to mitigate the cytotoxic and pro-inflammatory outcomes of LMP.
Our studies are the first to utilize Atg5fl/flLysM-Cre+ mice to test the contribution of
autophagy in macrophages to silica-induced NLRP3 inflammasome activity and
chronic disease. Others have utilized this mouse model to test the role of myeloid
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cell-mediated autophagy in inflammation and disease burden with Mycobacterium
tuberculosis [139]. In that report, inflammation and disease were significantly
enhanced in Atg5fl/flLysM-Cre+ mice compared to littermate controls. A second study
by different investigators reported enhanced inflammation and disease with LPS
and/or Bleomycin induced lung injury in Atg7fl/flLysM-Cre+ mice, which are also
defective in autophagosome formation [146]. Likewise, we observed significantly
greater levels of pro-inflammatory mediators IL-18 and HMGB1 (Figure 5), increased
extracellular LDH, and chronic disease (Figure 6) in Atg5fl/flLysM-Cre+ mice with silica
exposure. The studies strongly support an integral role for autophagy as an important
mechanism in suppressing cell death with silica exposure as well as mitigating
NLRP3 inflammasome activity.
Two additional important findings in this study include the observation that silica
exposure increases IL-18 and HMGB1 (Figure 4), and release of these proinflammatory mediators is enhanced in autophagy deficient mice. HMGB1 is a
nuclear architectural protein that is actively secreted from macrophages with active
NLRP3 inflammasomes, and is passively released from dead or dying cells [19, 18,
11]. Extracellular HMGB1 acts as a Danger Associated Molecular Pattern, and can
contribute to sterile priming of the NLRP3 inflammasome [100]. Exacerbated HMGB1
levels in the lavage fluid of silica-exposed Atg5fl/flLysM-Cre+ mice are consistent with
increased cell death (Figure 4). The observation that Atg5fl/flLysM-Cre+ have
increased neutrophil numbers at baseline (Figure 5), and high levels of HMGB1 after
silica exposure could be due, in part, to more neutrophil cell death, though this was
not investigated in these studies. The presence of high levels of both IL-18 and
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HMGB1 in autophagy deficient mice, and greater chronic disease, indicate that these
two inflammatory mediators could contribute more to particle-induced chronic lung
disease than appreciated. IL-1R null mice exposed to Multi-walled Carbon Nanotubes
(another particle that activates the NLRP3 inflammasome), while protected from
excessive acute inflammation, develop more severe chronic disease [78]. These
studies indicate that IL-1R signaling may not be as important in chronic disease, but
rather other signals including IL-18 and/or HMGB1 could be more important
contributors to chronic pathology. This notion is further supported by the fact that we
observed spontaneous IL-18 release and some lung pathology in PBS-exposed
autophagy deficient mice (Figure 4C, Figure 6B). Others have also reported
increased neutrophils, IL-18, and spontaneous disease at baseline in Atg7fl/flLysMCre+ mice [146]. IL-18 neutralizing antibodies but not Anakinra, the IL-1R antagonist,
were effective at reducing spontaneous disease in Atg7fl/flLysM-Cre+ mice [146]. This
may likely be true for Atg5fl/flLysM-Cre+ mice, though this was not determined. Finally,
IL-18 and HMGB1 have been implicated in autoimmune disorders such as SLE,
which has greater prevalence among individuals with silicosis [25, 24]. Further
studies will be needed to elucidate the role of HMGB1 and IL-18 in silica-induced lung
inflammation and its subsequent contribution to systemic disease.
An additional novel finding of this work is that the macrophages in Atg5fl/flLysMCre+ mice were significantly larger than littermate controls. Defective autophagy has
been reported to negatively impact lipid metabolism and cholesterol trafficking [149],
and contribute to foam cell formation in atherosclerosis [150]. Foam cells have been
observed in silicosis, and may contribute to the fibrotic response [151]. While the
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mechanism responsible for larger AM was not investigated, future studies should
include further characterization of AM populations from autophagy-deficient mice,
including assessing the impacts of Atg5 depletion in macrophages on foam cell
formation.
In conclusion, silica exposure increases autophagic activity in macrophages in
vitro and vivo. Knocking out Atg5, which is required for autophagosome formation,
causes enhanced acute inflammation (predominantly HMGB1 and IL-18 release),
increased cell death, and exacerbated chronic disease (see Figure 7). Furthermore,
Atg5 depletion causes spontaneous NLRP3 inflammasome activity and disease, with
IL-18 being the predominant NLRP3 inflammasome cytokine being released. These
studies show the importance of autophagy in macrophages to suppressing silicainduced inflammation and cytotoxicity that drive chronic disease, and maintaining
lung homeostasis. The mechanisms described in these studies may also be critical
for suppression of inflammation and disease following exposure to other NLRP3
inflammasome activating particles including asbestos, uric acid crystals, cholesterol
crystals, and engineered nanoparticles, and supports future studies of the role of
autophagy with exposure to these agents.
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Figure 4.1. Autophagy is increased in vitro in BMdM 24 hr following silica exposure.
(A) Representative images of GFP-LC3 expression in BMdM following exposure to
silica (100 µg/mL) with or without Bafilomycin A1 treatment (100 µM) and 3-MA
treatment (5 µM). Images were captured using a 60X scan (B) Average GFP-LC3
puncta per cell for combined experiments (N=3). (C) Median Fluorescent Intensity
(MFI) of combined experiments (N= 3). (D) Representative western blot of three
separate experiments showing LC3, p62, and total ubiquitination levels in BMdM
exposed to silica with or without Bafilomycin A1 treatment (100 µM). Graphs show
median ± SEM. *P < 0.05 indicates significance with two-way ANOVA and a onetailed post test.
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Figure 4.2. Silica exposure increases autophagy in AM in vivo. (A) Cell counts in the
lung lavage fluid 7 d after silica exposure (40 mg/kg). (B) Representative Western
Blot and densitometry graph of combined experiments showing LC3 and p62 levels in
isolated AM 7 d following instillation of silica (40 mg/kg). (C) Representative images
of AM isolated 7 d post silica exposure in GFP-LC3 mice (60X). N=4 for each
treatment group. 2 mice were pooled for each N for sufficient protein for Western Blot
analysis. Graphs show mean ± SEM. *P < 0.05, ***P < 0.001 indicates significance
over PBS-exposed mice using a two-tailed t-test.
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FIGURE 3
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Figure 4.3. Autophagy deficient BMdM are more susceptible to cell death and have
enhanced HMGB1 release. BMdM were exposed to silica (100 µg/mL) and LPS (20
ng/mL) and cell supernatants or lysates assessed after 24 hr. (A) Representative
Western Blot showing defective autophagy in Atg5fl/flLysM-Cre+ mouse BMdM,
indicated by impaired LC3-I lipidation to LC3-II. (B) IL-1β levels in cell supernatants
24 hr after particle exposure. (C) Percent extracellular LDH activity in cell
supernatants (compared to activity from total cell lysates). (D) Extracellular HMGB1
24 hr after particle exposure. Graphs show mean ± SEM (N=6 for each group). *P <
0.05, ***P < 0.001 indicate significance with 2-way ANOVA.
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Figure 4.4. Atg5 depletion in macrophages in vivo enhances acute inflammation.
Autophagy deficient and littermate control mice were instilled with 40 mg/kg silica or
PBS and assessed for indicators of inflammation in the lavage fluid after 24 hr
including: (A) Total protein, (B) HMGB1, (C) IL-18, (D) IL-1β, (E) LDH, and (F)
cathepsin activity. Graphs show mean ± SEM (N=8 for all treatment groups). *P <
0.05, **P < 0.01, ***P < 0.001 compared to silica-exposed littermate control using a 2way ANOVA.
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Figure 4.5. Basal phenotype observed in Atg5fl/flLysM-Cre+ mice. Autophagy deficient
and littermate control mice were instilled with 40 mg/kg silica or PBS and assessed
sacrificed after 24 hr. (A) Total combined cell counts, and macrophage and neutrophil
counts in the lavage fluid. (B) CXCL1 levels in the lavage fluid. (C) IL-1α levels in the
lavage fluid. (D) Cytospins showing increased macrophage area on slide. Black Bar
indicates 20 µm. Graphs show mean ± SEM (N=8 mice per treatment group). *P <
0.05, **P < 0.01, **P < 0.001 when comparing to PBS-exposed littermate control.
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FIGURE 6
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Figure 4.6. Atg5 depletion in macrophages in vivo results in enhanced pathology and
collagen deposition with silica exposure. Mice were exposed to silica (40 mg/kg) once
a week for 4 consecutive weeks, and then sacrificed 28 days following the final
instillation (day 56). (A) H&E stained lung sections showing increased pathology. (B)
Trichrome stained sections showing increased collagen and pathology. Images were
captured at 20X magnification. Graphs show mean rank score ± SEM (N=3 for each
treatment group) *P < 0.05, **P < 0.01 indicates significance following rank
transformation and post-hoc analysis using the Kruskal-Wallis test with Dunn’s
multiple-comparison post test.
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FIGURE 7

Figure 4.7. Model of autophagy suppression of NLRP3-inflammasome associated
inflammation and cytotoxicity. Silica exposure causes phagolysosome membrane
permeabilization resulting in the release of lysosomal contents into the cytosol
including cathepsins. This results in both activation of the NLRP3 inflammasome and
damage of cellular proteins and organelles, and leads to cytotoxicity. Mitochondrial
damage, which results in ROS, is used as a representative example of downstream
consequences of LMP. Autophagy is increased following silica exposure in order to
suppress NLRP3-inflammasome activity and rescue cells from cytotoxicity, and
thereby mitigate chronic inflammation and disease.

123

5.0. CHAPTER 5: UNIFYING THEORY
5.1. Overview
Chronic NLRP3 inflammasome activity is critical to the development of multiple ILD.
The studies in this dissertation address specific gaps of knowledge related to NLRP3
inflammasome activation and persistence in macrophages in the lungs following
bioactive particle exposure. Summaries of critical findings for each manuscript,
limitations, and proposed future studies are discussed below. A unifying theory of the
the mechanisms and consequences of lysosome membrane permeabilization based
on the findings in these studies are summarized in the unifying model (Figure 5.1)

5.2. HMGB1 participates in NLRP3 inflammasome priming
The current two hit hypotheses for particle-induced NLRP3 inflammasome
activity includes priming by an endogenous alarmin (signal 1), and NLRP3
inflammasome assembly (Signal 2) which results from LMP. Signal 1 had not hitherto
been determined with particle exposures. We identify HMGB1 as participating in
priming of the NLRP3 inflammasome with MWCNT exposure in Chapter 2. Central
findings of Chapter 2 are summarized below:
•

HMGB1 is released from macrophages and epithelial cells
following MWCNT exposure (Figure 1.1)

•

HMGB1 secretion from macrophages is dependent on
caspase-1 (Figure 1.1, Figure 3.5)

•

Extracellular HMGB1 participates in priming of the NLRP3
inflammasome with MWCNT exposure (Figure 2.2, 2.3).
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While this relationship was not assessed for other particle
exposures, we predict a similar activity in other models of
sterile injury.
A Specific redox form of HMGB1 has been proposed to promote NF-κB activity
[100, 22]. In these studies, a disulfide bride between cysteine residues C23 and C45
and a cysteine residue C106 are reported to be important for binding to TLR4. Our
data suggest that the specific NF-κB activating redox HMGB1 isoform did not prime
the NLRP3 inflammasome (Figure 2.2), suggesting other potential isoforms or
HMGB1 complexes were responsible. Future studies should include identifying the
HMGB1 isoform in vivo responsible for NLRP3 inflammasome priming. Necrosis and
lysosome mediated cell death was observed following bioactive particle exposure, so
it is very possible that HMGB1 is associated in immune complexes that may include
nucleic acid. HMGB1/DNA immune complexes have been implicated in SLE, which
has increased prevalence in individuals with chronic lung disease associated with
particle exposure [25, 29, 3]. Therefore, future studies should include measuring
HMGB1/DNA immune complexes in serum following particle exposure and in
individuals with chronic lung diseases. The studies were performed at an acute time
point (24 hr), which does not necessarily mean HMGB1 contributes to continuous
priming of the NLRP3 inflammasome, driving chronic disease. However, HMGB1 was
present in high levels in the lavage fluid 7 d after silica exposure, and was being
secreted from macrophages at this time point (Figure 3.5, 3.6). Increased HMGB1
levels have also been observed 4 d following MWCNT exposure (data not shown).
These data are consistent with HMGB1 driving persistent NLRP3 inflammasome
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activity. Future studies should include administration of HMGB1 neutralizing
antibodies or A-box (the truncated form that acts as a competitive receptor antagonist
[152]) in order to test the role of HMGB1 in driving persistent NLRP3 inflammasome
activity and the development of ILD.

5.3. LMP and Cathepsin B drive persistent NLRP3 inflammasome activity
Studies on the role of HMGB1 in priming the NLRP3 inflammasome revealed
that secretion was dependent upon active caspase-1. The next logical step was to
investigate whether HMGB1 secretion was dependent upon upstream activators of
the NLRP3 inflammasome, including cathepsin B. We identified cathepsin B activity
as the critical pathway driving persistent NLRP3 inflammasome activity and HMGB1
release with particle exposure. LMP results in cathepsin release into the cytosol,
which can, in turn, drive persistent NLRP3 inflammasome activity. These studies
suggest targeting cathepsin B and/or LMP may block both signal 1 and signal 2, and
effectively reduce persistent NLRP3 inflammasome activity following particle
exposure. Important findings from Chapter 3 are summarized below:
•

Particle-induced LMP is dependent upon Phagolysosome
acidification (Figure 3.2, Figure 3.3)

•

Silica exposure causes LMP in vivo (Figure 3.3.)

•

Active Cathepsin B regulates active Cathepsin L (Figure 3.2,
Figure 3.3)

126

•

Cytosolic cathepsin B (following LMP) drives persistent
NLRP3 inflammasome activity and HMGB1 secretion (Figure
3.6)

The dependence of HMGB1 and cathepsin secretion on active caspase-1
supports the notion that the NRLP3 inflammasome regulates unconventional
secretion. Others have reported this as well, and suggest autophagy is a platform by
which NLRP3 inflammasome associated cytokines and HMGB1 are packaged [66,
11]. The Golgi Reassembly and Stacking Protein (GRASP) is reported to be
associated with the unconventional secretosome [66]. Despite these reports,
unconventional secretion mechanisms remain largely undetermined.
A second important finding presented in Chapter 3 includes the dependence of
cathepsin L activation on active cathepsin B. These data have significant implications
challenging the current hypothesis that cathepsin B or associated substrates could be
directly responsible for binding NLRP3. Others have reported that NLRP3
inflammasome activation is not defective in cathepsin-B deficient macrophages,
raising doubts on the specificity of cathepsin B following LMP. Multiple cathepsins
may facilitate NLRP3 inflammasome activation with particle exposure [13, 153]. Our
findings support this notion. Future studies should include determining the relative
contribution of other lysosomal cathepsins to NLRP3 inflammasome activation
following particle-induced LMP.
Finally, we hypothesize that targeting LMP and cathepsin B may be a viable
approach to reducing both signal 1 and signal 2 following particle exposures. It is
important to consider that while LMP is a common event driving particle-induced
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LMP, other downstream factors likely contribute to the divergence of ILD. In order to
target LMP more effectively, it will be necessary to understand how particles induce
LMP. We show that phagolysosome acidification is necessary for particle-induced
LMP. The protein corona has been implicating in decreasing particle bioactivity,
possibly through buffering membrane interactions [113]. While these studies do not
directly address how particles cause LMP, they provide significant support that the
protein corona may be important in buffering particle-induced LMP. Further, our
findings support that specific physiochemical characteristics of the particles define
both their LMP and downstream NLRP3 inflammasome activating potential. With the
adaptation of the LMP assay developed by Aits et al [60], these associations between
particle physiochemical characteristics and LMP-inducing potential can now be more
readily quantified. Future studies should include altering particle physiochemical
characteristics (size, shape, charge, solubility, protein corona etc.) and measuring
LMP using this assay.

5.4. Autophagy suppresses silica-induced inflammation and lung disease
Autophagy is reported to be a primary degradation pathway for NLRP3 and AIM
inflammasomes [71, 147, 72]. Furthermore, autophagy may be protective during
cellular injury. The contribution of autophagy in macrophages to particle-induced
inflammation and disease had not hitherto been determined. We hypothesized that
autophagy would be an important mechanism for suppressing silica-induced
cytotoxicity and inflammation. Important findings of Chapter 4 are summarized below.
•

Silica exposure increases autophagy (Figure 4.1.,4.2.)
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•

Autophagy deficiency enhances cytotoxicity in macrophages
in vitro (Figure 4.3.)

•

Autophagy deficiency in macrophages enhances NLRP3
inflammasome activity (primarily IL-18), HMGB1 secretion,
and cytotoxicity in vivo (Figure 4.4.)

•

Knocking out autophagy in macrophages causes basal
inflammation and altered macrophage phenotype (Figure
4.5.)

•

Autophagy deficiency in macrophages results in chronic lung
disease, which is further exacerbated with silica exposure
(Figure 4.6)

Findings from chapter 4 support our hypothesis that autophagy is a
mechanism to suppress cellular injury and inflammation with silica exposure. An
important observation was that in autophagy deficient mice, IL-18 was significantly
increased as well as chronic pathology. Furthermore, HMGB1 release was greatly
enhanced. This would suggest greater roles for IL-18 and HMGB1 in driving chronic
lung disease than previously appreciated. Future studies should include assessing
the dependence of chronic disease on IL-18 and HMGB1.
Enhanced autophagy via overexpression of Atg5 has been reported to provide
an overall protective advantage in mice challenged with oxidative stress, and can
increase their lifespan [154]. In addition to sequestering damaged cellular
components the NLRP3 inflammasome, autophagy has been reported to facilitate
recapture of permeabilized lysosomes following acute kidney injury [155]. Whether
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this is true for macrophages in the lungs following silica and other ENM exposures
has not been determined, but may be an additional mechanism of cellular survival.
Enhancing autophagy as a possible therapeutic approach was not investigated in
these studies, but should be included in future research.

5.5. Unifying Theory
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Figure 5.1. Mechanisms and consequences of LMP following exposure to bioactive
particles. The model depicted illustrates common mechanisms contributing to
persistent NLRP3 inflammasome activity following bioactive particle exposure in
macrophages. Following inhalation, bioactive particles are phagocytosed by lung
macrophages. The phagosome containing the particle matures in the endocytic
pathway and fuses with lysosomes in order to degrade the particle. The low pH of the
phagolysosome allows for removal of the protein/lipid corona surrounding the particle,
which could lead to particle-membrane interactions. Inhibition of lysosomal vATPases
with Bafilomycin A1 prevents LMP, highlighting the importance of acidification in
licensing particles or other endogenous mechanisms to cause LMP. Following LMP,
cathepsins translocate into the cytosol facilitating NLRP3 inflammasome activation
and causing intracellular damage. NLRP3 inflammasome assembly and activation of
caspase-1 mediates the unconventional secretion pathway for cytokines, HMGB1,
and cathepsins. Once actively secreted or released from dying cells, extracellular
HMGB1 can participate in priming of the NLRP3 inflammasome. Additionally, particle
exposure causes cellular injury resulting in increased autophagic induction.
Autophagy acts to suppress NLRP3 inflammasome activity and cytotoxicity, however
in the face of LMP, autophagy may not function normally. Future research should
include assessing the therapeutic merit of inhibiting LMP and/or HMGB1 release, or
enhancing autophagy in the context of murine models of particle-induced ILD and
models of ILD not associated with particle exposure.
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